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Federal support and funding for human embryonic stem cell (hESC) research in the 
United States lags behind stem cell programs in many countries because of the divisive 
debate over hESC research and the continually evolving federal policies that have 
hindered research efforts. The purpose of this phenomenological study was to explore the 
perceptions of stem cell researchers, stakeholders, and investors in the United States 
about the effects of the current federal stem cell policy on stem cell research in the United 
States, the moral disagreement with stem cell research, and their recommendations to 
improve stem cell research policy in the United States. Rogers’s diffusion of innovation 
theory and Kingdon’s agenda-setting theory served as the theoretical frameworks for this 
study. Data were collected through telephonic semistructured interviews with a snowball 
sample of 21 participants. Data were analyzed using Attride-Stirling’s 6 steps of thematic 
coding. Findings indicated the need to educate laypersons and legislators, involve the 
public in the stem cell research policy debate, increase federal funding, and exclude 
religious considerations from political discussions. The implications for positive social 
change are directed at stem cell policymakers to focus attention and resources on creating 
a cohesive federal hESC funding policy to ensure that stem cell research improves in the 
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Chapter 1: Introduction to the Study 
 The uncertain stem cell policies in the United States have been a great challenge 
for stem cell researchers, especially for those who work with human embryonic stem 
cells (hESCs; Levine, 2011). Levine (2011) reported that in 1995, President Clinton 
banned federal funding for research that would destroy human embryos. In 2001, the 
Bush administration’s restriction resulted in only 21 viable lines that could be used in 
federally funded research. However, in 2009, President Obama issued an executive order 
(EO) with the goal of strengthening hESC research in the United States (Levine, 2011; 
Nature Cell Biology, 2010). President Obama’s new stem cell policy, however, did not 
approve the 21 hESC lines that were eligible under the Bush administration (Levine, 
2011). Nature Cell Biology (2010) reported that hESC lines have to meet the National 
Institutes of Health (NIH) strict ethical policies. According to the NIH (2015a), applicant 
institutions proposing research using hESCs derived from embryos donated in the United 
States should be derived from human embryos that were created using in vitro 
fertilization (IVF) for reproductive purposes and were no longer needed for this purpose. 
In addition, the hESCs should be donated by individuals who sought reproductive 
treatment and gave voluntary written consent for the human embryos to be used for 
research purposes. Therefore, it is still not possible to create new hESC lines from viable 
embryos using federal funds, and verifying that the hESC lines were derived from donors 
who had given their informed consent has been very time-consuming for researchers 
(Nature Cell Biology, 2010). Questions still remain as to whether U.S. stem cell 




 The use of hESCs in stem cell research has been a very divisive and controversial 
issue (Levine, 2011; Mintrom, 2013). Mintrom (2013) discussed morality politics that are 
associated with hESC research. Mintrom noted that hESC research is controversial 
because it raises questions about what counts as human life and who gets to make that 
decision. Sano (2013) argued that for hESC research to flourish in the United States, a 
cohesive federal hESC public financing policy is needed. In this phenomenological study, 
I explored the perceptions of 21 stem cell researchers, stakeholders, and investors in the 
United States regarding the effects of the current federal stem cell policy on stem cell 
research in the United States, the moral disagreement with stem cell research, and 
recommendations to improve stem cell research policy in the United States. Stem cell 
researchers are scientists who study the biological properties of stem cells and the 
potential use and effect of stem cells in treating diseases (NIH, 2009). Stakeholders are 
“individuals whose collective actions are guided by or directly serve the mandate of an 
overarching organizational framework” (Downey & Geransar, 2008, p. 70). Stakeholders 
play a major role in the stem cell debate as well as in stem cell research and policy 
development, such as patient groups in alignment with the medical community (Downey 
& Geransar, 2008). Investors are individuals who invest in stem cell research with the 
intent on making a profit (Zucchi, 2015). 
This study was significant because findings may encourage stem cell 
policymakers to focus attention and resources on creating a cohesive, bipartisan federal 
hESC funding policy to ensure that stem cell research succeeds in the United States. 




health care field. Chapter 1 includes the background of the study, statement of the 
problem, purpose of the study, research questions, theoretical framework, nature of the 
study, definition of terms, assumptions, scope and delimitations, limitations, significance 
of the study, and a summary. 
Background of the Study 
In the late 1990s, breakthroughs in the cloning of mammals and the isolation of 
hESC lines resulted in science policy debates at the national and state levels (Levine, 
Lacy, & Hearn, 2013). Levine et al. (2013) indicated that these debates tend to focus on 
hope and controversy of these scientific breakthroughs. Levine et al. noted that most 
scientists believe that hESC research offers great promise in understanding human 
disease and developing treatments for conditions that are currently untreatable. Other 
researchers have noted that hESC research may provide advances in treatment of 
numerous diseases and may provide stem-cell-based therapies for a number of conditions 
such as strokes, spinal cord injuries, Alzheimer’s disease, and Parkinson’s disease 
(California Institute for Regenerative Medicine [CIRM], 2015b; Holland, Lebacqz, & 
Zoloth, 2001; Mason & Manzotti, 2010).  
However, hESC research is controversial because it involves the use and 
destruction of early human embryos (Levine, 2011; Levine et al., 2013; Mintrom, 2013). 
Levine et al. (2013) reported that for hESC research to reach its highest potential, cloning 
technology may be needed to create embryos that are genetically matched to potential 




technique has been performed only in animals, it creates controversy because it is viewed 
as creating an opportunity for the cloning of humans for reproductive purposes.  
Due to these scientific advances, President Clinton banned the use of federal 
funds for human cloning (Levine et al., 2013). With the successful isolation of hESCs in 
1998, a legal review was conducted by the National Bioethics Advisory Committee 
(NBAC) in 1999, which indicated that the federal government could legally fund hESC 
research; however, funds could not be used for derivation of stem cell lines (Levine et al., 
2013; Walter, 2001). Levine et al. (2013) reported that in 2000, the Clinton 
administration issued guidelines supporting research in the stem cell field, and the NIH 
invited scientists to apply for research funding. However, before the Clinton 
administration guidelines could be adopted and the first grant meeting could take place, 
President Bush was elected. Levine et al. noted that in 2001, President Bush restricted 
federal funds for hESC research on existing stem cell lines. In 2009, the Obama 
administration relaxed some of the Bush administration’s restrictions on federal funding 
for hESC research, such as authorizing the use of federal funds on ethically derived hESC 
lines despite the date of derivation; however, the implementation of this policy has been 
hindered by legal challenges (Levine, 2011; Levine et al., 2013; Nature Cell Biology, 
2010). For example, the Dickey-Wicker Amendment (the amendment) was the response 
of the Republican-controlled House and Senate to ethical concerns surrounding federal 
funding for research involving human embryos. Since 1996, the amendment has been 
attached to appropriations bills for the Department of Health and Human Services, Labor, 




funding for hESC research (Couch, Lane, & Black, 2012; Levine, 2011; Levine et al., 
2013). 
Due to the divisiveness of the hESC research debate, a cohesive or bipartisan 
federal ESC public financing policy is still uncertain (Levine, 2011; Levine et al., 2013; 
Mintrom, 2013; Sano, 2013). As a result, hESC researchers face continued policy 
fluctuations, legal challenges, and other hurdles to their future research (Levine, 2011; 
Levine et al., 2013; Mintrom, 2013; Sano, 2013). A review of literature indicated that 
there is a gap in stem cell research that focuses on U.S. stem cell researchers’, 
stakeholders’, and investors’ perceptions regarding the effects of the current federal stem 
cell policy on stem cell research in the United States, the moral disagreement with stem 
cell research, and recommendations to improve stem cell research policy in the United 
States; in this phenomenological study, I addressed that gap. This study was needed to 
encourage policymakers to focus attention and resources on creating a consistent federal 
hESC funding policy to ensure that stem cell research succeeds in the United States. 
Statement of the Problem 
On March 9, 2009, President Obama issued EO 13505, Removing Barriers to 
Responsible Scientific Research Involving Human Stem Cells, which changed the way the 
NIH can support and conduct human stem cell research (NIH, 2011). The EO removed 
limitations on scientific inquiry and expanded the NIH support for the exploration of 
stem cell research, with the purpose of enhancing the contributions of U.S. scientists to 
make important discoveries and create new therapies for the benefit of humanity (Obama, 




research, questions remain about the extent to which U.S. stem cell researchers have 
benefited from this more relaxed federal funding policy (Nature Cell Biology, 2010; 
Wolinsky, 2009).  
The problem is that despite the new federal stem cell policy, federal support and 
funding for hESC research in the United States are still behind stem cell programs in 
many countries, and the evolving federal policies have hindered research efforts (Nature 
Cell Biology, 2010). Nature Cell Biology (2010) reported that although federal funds can 
now be used for research on any hESC line that is found to meet the NIH’s strict ethical 
policies, creating new hESC lines from viable embryos using federal funds is still not 
possible. Mintrom (2013) noted that hESC research is controversial because 
consideration has to be given to what counts as human life and who gets to make that 
decision. In addition, Nature Cell Biology related that an essential element of NIH 
approval is verifying that hESC lines were derived from donors who provided informed 
consent, and this has proven to be extremely time-consuming. As of July 2010, 64 hESC 
lines were eligible for use in research supported by U.S. federal funds. In contrast, 120 
hESC lines are available in the United Kingdom (UK) Stem Cell Bank registry, and new 
hESC lines can be created in the UK, which are subject to licensing by the Human 
Fertilization and Embryology Authority. China, Japan, and some European countries 
such as Belgium and Sweden have similarly liberal policies regarding the creation of new 
hESC lines.  
Although it is unavoidable that each state government will set restrictive policies 




liberal policy at the federal level could soften the tone of the hESC debate and promote 
greater acceptance of such research within the United States (Nature Cell Biology, 2010). 
From a policy perspective, more remains to be done to ensure that stem cell research 
flourishes in the United States. A qualitative phenomenological study was needed to 
explore the perceptions of stem cell researchers, stakeholders, and investors in the United 
States about the effects of the current federal stem cell policy on stem cell research in the 
United States, the moral disagreement with stem cell research, and recommendations to 
improve stem cell research policy in the United States. 
Purpose of the Study 
The purpose of this phenomenological study was to explore the perceptions of 21 
stem cell researchers, stakeholders, and investors in the United States about the effects of 
the current federal stem cell policy on stem cell research in the United States, the moral 
disagreement with stem cell research, and recommendations to improve stem cell 
research policy in the United States. There are many different types of stem cells, each 
with different potential to treat disease (CIRM, 2013). The CIRM (2013) reported that 
adult stem cells come from any organ, are the source of new cells throughout the life 
of the organism, and are also called tissue stem cells. “The pluripotent cells, which have 
the ability to form all cells in the body, can be either embryonic or induced pluripotent 
stem (iPS) cells” (CIRM, 2013, para. 1). 
Stem cell researchers, biotechnology companies, and laboratories are highly 
mobile actors who have the ability to relocate in response to liberal regulatory 




and Alt (2012), commercial companies have created active research programs to develop 
stem cell technologies and therapies. Due to electoral politics and federal restrictions on 
publicly funded stem cell research, some states have provided their own legislation and 
significant public funding to promote stem cell research. However, controversies over 
hESC research continue, especially during tough economic times where there are 
concerns about losing jobs to other states or countries.  
Research Questions 
To explore the perceptions of 21 U.S. stem cell researchers, stakeholders, and 
investors about the effects of the current federal stem cell policy on stem cell research in 
the United States, the moral disagreement with stem cell research, and recommendations 
to improve stem cell research policy in the United States, I asked the following research 
questions: 
1. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the effects of the current federal stem cell policy on stem cell research 
in the United States? 
2. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the moral disagreement with stem cell research? 
3. What do U.S. stem cell researchers, stakeholders, and investors recommend to 
improve stem cell research policy in the United States? 
Theoretical Framework 
Rogers’s (1962) diffusion of innovation (DOI) theory and Kingdon’s (1995) 




overview of the theories is provided in this section with a more detailed explanation 
provided in Chapter 2. This section is organized in the following subsections: diffusion of 
innovation theory and Kingdon’s agenda-setting theory. 
Diffusion of Innovation Theory 
DOI theory refers to the process of how and why innovation of new ideas and 
technology are communicated to a culture or social system as well as the rate at which 
they spread (Rogers, 2003). There are four main elements in the DOI theory: innovation, 
communication channels, time, and social systems (Rogers, 2003, Sahin, 2006). 
According to Rogers (2003), innovation refers to an idea, practice, or object that an 
individual perceives to be new. Communication channels refer to the ways in which 
messages travel from one person to another. Time refers to the innovation-decision 
period, which is the length of time that is needed to pass through the innovation-decision 
process. Time also refers to the rate of adoption, which is the speed an innovation is 
adopted by members of a social system. Social systems refer to a set of interrelated units 
that are engaged in joint problem solving to accomplish a common goal.  
The innovation decision process consists of five stages of adoption: knowledge, 
persuasion, decision, implementation, and confirmation (Rogers, 2003). Sahin (2006) 
noted that in the knowledge stage, individuals learn about the existence of innovation and 
seek information about the innovation. In the persuasion stage, individuals have negative 
or positive attitudes toward the innovation; however, this does not always lead to an 
adoption or rejection of the innovation. In the decision stage, individuals choose to adopt 




Finally, in the confirmation stage, the innovation decision has been made, but individuals 
seek support for their decision. Dresser (2010) indicated that the debate over stem cell 
research offers an opportunity to examine a variety of ethical and policy issues raised by 
biomedical innovation. 
Kingdon’s Agenda-Setting Theory 
Kingdon’s agenda-setting theory refers to how agenda setting affects the policy 
process in the planning stages and how it shapes the behavior of others (Kingdon, 1995). 
Kingdon (2003) argued that governmental agenda pertains to subjects that people in and 
around government are giving serious attention. Kingdon described the policymaking 
process around three streams and a policy window (Soroka, 1999). Soroka (1999) 
reported that the three streams or processes are problems, policies, and politics. Kingdon 
(1995) described the problem stream as the process of convincing policy decision-makers 
to overlook one problem for another. Chayabunjonglerd (2012) observed that for public 
officials to create policies, there must first be problems that they can address through 
policymaking. For example, with the successful isolation of hESCs in 1998, problems 
with hESC research arose. The policy stream represents the process by which policy 
proposals are created, discussed, revised, and adopted for serious consideration (Kingdon, 
1995). Chayabunjonglerd noted that since 1998, many officials and interest groups have 
considered alternative policies on hESC issues. In 2001, these ideas were formulated into 
proposals, such as the Responsible Stem Cell Research Act of 2001. The open policy 




 In the politics stream, politics are political factors that influence agendas, such as 
changes in elected officials, political climate or mood (e.g., conservative, tax averse), and 
the voices of advocacy or opposition groups (Kingdon, 1995). Chayabunjonglerd (2012) 
reported that due to the opening of the policy window and the general public support of 
hESC research, intense political activity took place in Congress. Chayabunjonglerd noted 
that the majority of Democrats and moderate Republicans argued in support of hESC 
research. On the other hand, the majority of conservatives opposed hESC research. All 
three streams, plus the opening of the policy window, resulted in the issue of public 
funding for hESC being placed on the decision agenda. The possibility of change is at its 
greatest when all three streams come together (Soroka, 1999).  
Nature of the Study 
In this phenomenological study, I explored the perceptions of 21 stem cell 
researchers, stakeholders, and investors in the United States about the effects of the 
current federal stem cell policy on stem cell research in the United States, the moral 
disagreement with stem cell research, and recommendations to improve stem cell 
research policy in the United States. I chose a phenomenological design to explore 
participants’ experiences to obtain rich descriptions of a reaction to an event or 
phenomenon (see Creswell & Miller, 2000). This design allowed me to understand and 
reveal multiple facets of the issue (see Creswell & Miller, 2000). A phenomenological 
design provides an understanding of a phenomenon by revealing the meaning that 





Data were collected for this study through in-depth telephonic semistructured 
interviews with 21 stem cell researchers, stakeholders, and investors in the United States. 
The relationship between saturation and sample size was sufficient in this study because 
through the use of snowball sampling, I recruited 21 participants to obtain the richest data 
possible. Individual telephonic interviews were conducted at a time that was convenient 
for each participant. Using snowball sampling, which is a subset of purposive sampling, I 
recruited seven stem cell researchers, seven stem cell stakeholders, and seven stem cell 
investors to participate in the study. I contacted potential participants by e-mail or 
telephone. Selection criteria included men or women who were researchers at a 
government organization, private company, or university; faculty members at a univeristy 
where stem cell research was being conducted; or investors who worked for a 
government organization or private company that invests in stem cell research in the 
United States. Prospective participants were sent an invitation letter to participate in the 
study and were asked to recommend other stem cell researchers, stakeholders, or 
investors who met the selection criteria (see Appendix A). I transcribed the interviews, 
managed the data with NVivo, and analyzed the data using Attride-Stirling’s (2001) six 
steps of thematic coding. The study was conducted in accordance with Walden 
University’s Institutional Review Board (IRB) guidelines to ensure the ethical protection 
of research participants. The nature of the study is discussed in further detail in Chapter 
3. 
Definition of Terms 




Adult stem cells: Found in the various tissues and organs of the human body and 
thought to exist in most organs where they are the source of new cells throughout the life 
of the organism (CIRM, 2015a). They replace cells lost to natural turnover or to damage 
or disease (CIRM, 2015a). 
 Bioethics: “Bioethics is the application of ethics to the field of medicine and 
healthcare” (Center for Practical Bioethics, 2015, para. 1).  
Diffusion: “The process in which an innovation is communicated through certain 
channels over time among the members of a social system” (Rogers, 2003, p. 5). 
Diffusion of innovation (DOI) theory: The process of how and why innovation of 
new ideas and technology are communicated to a culture or social system as well as the 
rate in which they spread (Rogers, 2003). 
Embryonic stem cells (ESCs): Come from pluripotent cells, which exist only at 
the earliest stages of embryonic development and in humans, do not exist after about 5 
days of development (CIRM, 2015a). When isolated from the embryo and grown in a lab 
dish, pluripotent cells can continue dividing indefinitely. 
Groupthink: Groupthink occurs when a homogenous highly cohesive group is so 
concerned with maintaining unanimity that they fail to evaluate their alternatives and 
options (Janis, 1972). 
Innovation: An idea, practice, or object that a person perceives as new (Rogers, 
2003). 
Investors: In this study, individuals who invest in stem cell research with the 




In vitro: Embryos that have developed from eggs that have been fertilized outside 
of the body (Small & Doherty, 2011). 
Kingdon’s agenda-setting theory: How agenda setting affects the policy process 
in the planning stages and how it shapes the behavior of others (Kingdon, 1995). 
 Pluripotent cells: Pluripotent means many potentials, and “these cells have the 
potential of taking on many fates in the body, including all of the more than 200 different 
cell types” (CIRM, 2015a, para. 3). ESCs and induced pluripotent stem (iPS) cells 
(reprogrammed from adult tissues) are pluripotent cells (CIRM, 2005). 
 Stakeholders: In this study, “individuals whose collective actions are guided by or 
directly serve the mandate of an overarching organizational framework” (Downey & 
Geransar, 2008, p. 70). Stakeholders play a major role in the stem cell debate as well as 
in stem cell research and policy development, such as patient groups in alignment with 
the medical community (Downey & Geransar, 2008). 
Stem cell researchers: Scientists who study the biological properties of stem cells 
and the potential use and effect of stem cells in treating diseases (NIH, 2009). 
 Stem cells: “Have the ability to divide and create an identical copy of themselves, 
a process called self-renewal” (CIRM, 2015a, para. 2). In addition, stem cells “can also 
divide to form cells that mature into cells that make up every type of tissue and organ in 
the body” (CIRM, 2015a, para. 2). 
Assumptions 




• Stem cell researchers, stakeholders, and investors had experience with the 
stem cell research process. 
• Stem cell researchers, stakeholders, and investors would be willing to take 
part in the study because of its significance to focus attention and resources on 
creating a consistent federal hESC funding policy to ensure that stem cell 
research succeeds in the United States. 
• The in-depth telephonic semistructured interviews would be appropriate to 
explore U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the effects of the current federal stem cell policy on stem cell research 
in the United States, the moral disagreement with stem cell research, and 
recommendations to improve stem cell research policy in the United States. 
• The in-depth semistructured interview questions were worded so that the 
participants could understand the questions being asked.  
• The participants would honestly and openly answer the interview questions by 
sharing their perceptions about the questions asked. 
• The results of the study would lead to positive social change as findings are 
directed at stem cell policymakers to focus attention and resources on creating 
a consistent federal hESC funding policy to ensure that stem cell research 
succeeds in the United States. 
Scope and Delimitations 
The study’s participants included 21 stem cell researchers, stakeholders, and 




the current federal stem cell policy on stem cell research in the United States, the moral 
disagreement with stem cell research, and recommendations to improve stem cell 
research policy in the United States. I excluded stem cell researchers, stakeholders, and 
investors from other countries. I did not include anyone with whom I had a personal 
relationship, which included family members, friends, coworkers, or professional and 
personal associates. This prevented perceived coercion to participate due to any existing 
or expected relationship between the participants and me. However, I asked personal and 
personal associates if they knew individuals who fit the study criteria to get snowball 
sampling going.  
Limitations 
There were several limitations in this study. First, findings were limited by the 
snowball sample of seven stem cell researchers, seven stem cell stakeholders, and seven 
stem cell investors; each category of participants contained a smaller number than the 
overall sample of 21. Due to the small sample size for each category of participant, 
caution has to be taken in transferring the findings to similar populations of U.S. stem 
cell researchers, stakeholders, and investors. In addition, the results of the study may not 
be transferrable to other populations or countries. As a result, in future research, the 
sample population for each type of participant could be increased to achieve a broader 
understanding of their stem cell research policy experiences. In future studies, a different 
sampling strategy could also be used, such as random sampling. 
Second, social desirability bias was considered as stem cell researchers, 




have responded honestly to the interview questions. However, I assumed that participants 
would honestly and openly answer the interview questions by sharing their perceptions 
about the phenomenon. Third, there were limitations with self-reported data as 
participants may not have accurately or fully evaluated themselves. However, I assumed 
that participants accurately and fully self-evaluated.  
Significance of the Study 
Policy entrepreneurs, who are political figures who seek policy changes to 
existing areas of public policy, have faced significant opposition to government funding 
and favorable regulations to advance hESC research due to morality issues (Mintrom, 
2013). The most restrictive stem cell laws are in countries where Roman Catholicism is 
the dominant religion or Christian democratic parties are on the rise (Fink, 2008; 
Mintrom, 2013). Mintrom (2013) reported that the UK has a permissive approach to 
hESC research regulation and that it is correlated with the low percentage of adults who 
identify with the Roman Catholic faith (9%) in the UK. Mintrom noted that in the UK, 
moral issues have been widely investigated and extensively debated; however, they have 
not inhibited scientific research.  
Unlike in the UK and other permissive countries, hESC research in the United 
States is divisive and controversial, which has resulted in stem cell policy uncertainty 
(Levine, 2011; Levine et al., 2013; Mintrom, 2013). In 2010, 24% of Americans 
identified with the Roman Catholic faith (Pew Research Center, 2013, para. 11). There is 
no consistent federal hESC funding policy, which impedes the United States from being a 




hESC researchers continue to face policy fluctuations, legal challenges, and other hurdles 
to their research (Levine, 2011; Levine et al., 2013; Mintrom, 2013; Sano, 2013). There is 
a gap in stem cell research regarding U.S. stem cell researchers’, stakeholders’, and 
investors’ perceptions about the effects of the current federal stem cell policy on stem cell 
research in the United States, the moral disagreement with stem cell research, and 
recommendations to improve stem cell research policy in the United States. In this study, 
I addressed this gap by making an original contribution to the public policy and 
administration literature on this topic. Individuals working in public policy and 
administration, including the fields of biology and regenerative medicine and agencies 
such as the CIRM and the NIH, may be interested in the findings.  
Findings may encourage policymakers to focus attention and resources on 
creating a cohesive federal hESC funding policy to ensure that stem cell research 
succeeds in the United States. Implementation of a bipartisan federal hESC funding 
policy may lead to positive social change in the health care field as hESCs can be used 
for cell-based therapies to replace ailing or destroyed tissues resulting from macular 
degeneration, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and 
rheumatoid arthritis (NIH, 2015b). In addition, hESCs can be used to treat Alzheimer’s 
and Parkinson’s disease; however, the need for transplantable tissues and organs far 
outweighs the available supply (CIRM, 2015b; NIH, 2015b).  
Summary 
I explored seven U.S. stem cell researchers’, seven U.S. stakeholders’, and seven 




stem cell research in the United States, the moral disagreement with stem cell research, 
and recommendations to improve stem cell research policy in the United States. Data 
were collected using in-depth telephonic semistructured interviews. Using snowball 
sampling, I recruited 21 participants for the study. Findings may encourage stem cell 
policymakers to focus attention and resources on creating a more unified federal hESC 
funding policy to ensure that stem cell research succeeds in the United States. A cohesive 
federal hESC funding policy may lead to positive social change in the health care field by 
creating cell-based therapies to replace ailing or destroyed tissues. 
In Chapter 1, I included the introduction, background of the study, statement of 
the problem, purpose of the study, research questions, theoretical framework, nature of 
the study, definitions of terms, assumptions, scope and delimitations, limitations, 
significance of the study, and a summary. In Chapter 2, I include the introduction, 
literature search strategy, theoretical foundation, Dickey-Wicker Amendment, United 
States national policies, international communities’ stem cell policies, bioethics and the 
moral debate, embryonic stem cell research, and a summary and conclusions. In Chapter 
3, I include the research design and rationale, role of the researcher, methodology, issues 
of trustworthiness, and a summary. In Chapter 4, I include the introduction, setting, 
demographics, data collection, data analysis, evidence of trustworthiness, results, and a 
summary. In Chapter 5, I include the introduction, interpretation of findings, limitations 




Chapter 2: Literature Review 
In Chapter 2, I provide a review of relevant and current scholarly resources 
related to my study on the effects of the current federal stem cell policy on stem cell 
research in the United States, the moral disagreement with stem cell research, and 
recommendations to improve stem cell research policy in the United States. The literature 
review includes the introduction, literature search strategy, theoretical foundation, 
Dickey-Wicker Amendment, U.S. policies, international communities’ policies, bioethics 
and morality debate, embryonic stem cell research, and a summary and conclusions. 
According to Rogers (2003), innovation is adopted through a five-step process (i.e. 
relative change, compatibility, complexity, trialability, and observability). The problem is 
with constant change from one administration to the next, too much change hinders 
policy growth and development.  
Literature Search Strategy 
 I searched all Walden University library databases including ProQuest and 
EBSCOhost databases such as Academic Search Complete, Health and Medical 
Complete, LexisNexis Academic, and PubMed. In addition, I searched Gwinnett County 
Public Library databases. Search terms included public policy and human embryonic stem 
cell, public policy funding for stem cells, historical innovation on stem cells, U.S. policy 
on stem cell development, Obama policy on stem cells, Bush policy on stem cell research, 
and legislative policies or statutes on stem cells. I examined additional articles after 




examined relevant organizational websites such as the NIH and placed emphasis on the 
most recent literature. 
Theoretical Foundation 
Rogers’s (1962) DOI theory and Kingdon’s (1995) agenda-setting theory served 
as the theoretical foundation of this phenomenological study. This section is organized in 
the following subsections: diffusion of innovation theory and Kingdon’s agenda-setting 
theory. 
Diffusion of Innovation Theory 
Rogers’s (1962) DOI theory is used to explain how an idea or product gains 
momentum and diffuses through a specific population or social system. According to 
Rogers (1995), the goal of diffusion is for people who are part of a social system to adopt 
a new idea, behavior, or product as new or innovative. Rogers reported that the DOI 
theory addresses how policy and agendas are set, how policy moves through the political 
process, and the effect of policy once it is created. The purpose of diffusion is to create a 
dialogue with those who are against change.  
What is learned from previous innovations results in more advanced innovations 
being created and adopted (Rogers, 1995). Rogers (1995) related that the success of an 
innovation determines the rate of adoption for a similar innovation. Rogers noted that 
groupthink tends to limit the spread of innovation. Leaders of a group exert influence 
over the behaviors and beliefs of individuals and adopters in their networks (Anderson, 




growth (Amidon, 2005). According to Amidon (2005), individuals in political or social 
settings tend to accept groupthink as a form of solidarity and unanimity. 
 Groupthink, diffusion, innovation, and adopter are important terms in DOI theory. 
Groupthink was first introduced by Janis in 1972 to explain why groups sometimes make 
poor decisions. According to Kretchmar (2009), groupthink comes from the application 
of those who were part of a political advisory group to four U.S. presidents. Groupthink 
is often used when one cannot explain a phenomenon, and is often seen in consensus 
seeking and when evidence is not readily available. Diffusion is the means of how 
information is shared among a group of people in a network. Diffusion may impede a 
new product, idea, or practice from being accepted by others of a particular culture or 
network (Rogers, 1995). Rogers (1995) noted that innovation is a new product or service 
being introduced to potential adopters. Adopters are those who are affected by the new 
product, and adopters’ behavior may be influenced by the opinion of a leader. 
 Diffusion of innovation is connected to an individual’s perception of a new 
product or service, while invention is new (Therin, 2012). Therin (2012) noted that with 
the perception of newness, there must be knowledge about the service or product; 
otherwise, that perception is not relevant. In addition, any new innovation must be known 
among the targeted population of potential adopters, and a clear perception should be 
established. Once the knowledge about the product and service has been conveyed, there 
should be a theoretical framework in place to rate the adoption of the new innovation. 
According to Rogers (2003), there are five factors that influence the adoption of 




trialability, and (e) observability. These factors can be seen in Figure 1 under the 
persuasion stage, which is one of the five innovation-decision processes: (a) knowledge, 
(b) persuasion, (c) decision, (d) implementation, and (e) confirmation. 
 
Figure 1. Five stages of Rogers’s (2003) innovation-decision process model. Reprinted 
from Diffusion of innovations (5th ed.), by E. Rogers, 2003: New York, NY: The Free 
Press. Copyright 2003 by the Free Press. This source was taken from Creative Commons 
3.0. 
 
Relative advantage is defined as the degree to which an innovation is perceived as 
better than available products or services (Therin, 2012). Therin (2012) reported that this 
can be measured in terms of quality, satisfaction, or social status. Compatibility is 
determined by the acceptability of social or religious norms in the country, which may 




the difficulty of understanding, implementing, integrating, and using an innovation. 
Trialability is the possibility of experimenting with an innovation before adopting it. 
Observability is the degree to which the results of the implementation of an innovation 
are visible. If potential adopters can witness what happens after an innovation is 
implemented, they will be reassured about other factors and potential concerns about 
health and safety.  
The persuasion stage occurs when individuals interested in the innovation actively 
seek information about the innovation (Rogers, 2003). The other four innovation-decision 
process stages include knowledge, decision, implementation, and confirmation. 
According to Rogers (2003), in the knowledge stage individuals are first exposed to an 
innovation, but they do not have information about it. In the decision stage, individuals 
consider the advantages and disadvantages of using the innovation and make decisions 
about whether to use or reject it. In the implementation stage, individuals use the 
innovation at different degrees depending on the situation. In the confirmation stage, 
individuals make final decisions about whether to continue to use the innovation.  
 According to Rogers (1995), there are six steps in the innovation-development 
process:  
1. Recognizing a problem or need: Research and development activities are 
started to address a problem or need, and scientists seek to produce research to 
find a solution to an issue. 
2. Basic and applied research: Research is conducted to determine whether there 




research, which provides a more scientific process to help eradicate practical 
problems. If this does not work, a new technology is designed to address the 
problem. 
3. Development: The development process involves new ideas designed to meet 
the needs of a particular audience. During the development phase, there is a 
high rate of uncertainty about the innovation while trying to meet the needs of 
its adopters. With regard to policy, regulation, and competitor’s perspective, 
the system of information exchange about technological innovation is a 
pervasive issue that can have an unwavering effect on the outcome. A new 
industry may be developed around a radical innovation.  
4. Commercialization: The product is ready for manufacturing, marketing, 
packaging, and distribution. The end product at the time of commercialization 
may include two or more innovations to facilitate a more widely acceptable 
product to potential adopters. 
5. Diffusion and adoption: This is the most difficult step in the innovation-
development process, which involves diffusing the product to potential 
adopters. As with all new products, there is pressure to move it to market due 
to the problem and need being high priority. Sometimes public funds are used 
until there is a positive outcome that will be beneficial to potential adopters. 
The move to market is when scientists seem to have the greatest concern 





6. Consequences: In this stage, the innovation addressed or did not address the 
original need or problem. 
Hematology inventions spread rapidly, and factors that affect the introduction, 
international diffusion, and durability of innovation use are not well understood 
(Gratwohl et al., 2010). Gratwohl et al. (2010) used the DOI theory as the theoretical 
foundation in their study. The researchers used 251,106 hematopoietic stem cell 
transplants from 591 teams in 36 European countries. Gratwohl et al. analyzed the 
increase and decrease in such transplants for breast cancer and chronic myeloid leukemia 
and the replacement of bone marrow by peripheral blood as the source of stem cells as 
processes of diffusion. The results indicated that gross national income per capita, World 
Bank category, team density, team distribution, team size, team experience, and team 
innovator status were all significantly associated with some or all of the changes. The 
researchers concluded that adoption of any new medical technology and its diffusion 
correlate with four main elements: economics, evidence, external regulations, and 
expectations. These four factors may form the basis for any process of diffusion. 
In the debate over ESC research, ethical and policy issues should be considered 
(Dresser, 2010). Dresser (2010) suggested that many of the ethical and policy issues that 
stem cell research presents apply to biomedical research in general, such as questions 
about appropriate research priorities and allocation of limited resources for research and 
health care. Dresser argued that the debate over stem cell research offers an opportunity 
to examine a variety of ethical and policy issues raised by biomedical innovation. Ethical 




Dresser noted that some individuals believe that there should be severe limits on research 
involving early human embryos, while others disagree. Dresser claimed that these 
disagreements cannot be settled by science because they are value conflicts. In struggling 
with these conflicts, Dresser suggested that individuals should maintain respect for those 
holding differing views and should look for policies that are consistent with as many of 
those views as possible. 
Kingdon’s Agenda-Setting Theory 
 Kingdon’s agenda-setting theory pertains to how agenda setting affects the policy 
process in the planning stages and how it shapes the behavior of others (Kingdon, 1995). 
According to Kingdon (1995), setting an agenda is the main step in the policy process. At 
this stage, the policy agenda is set up with a list of issues or problems that need to be 
reviewed by various government officials before their session for the year has ended. As 
the agenda is set and reviewed, a government official may decide to make changes to the 
order in which it is reviewed based on the priority assigned.  
 Kingdon (1995) described the policymaking process around three streams and a 
policy window. The three streams or processes are problems, policies, and politics 
(Kingdon, 1995). Kingdon described the three streams as follows: 
1. Problems: The process of convincing policymakers to overlook one 
problem for another. A particular policy proposal’s chance of rising on 
the agenda is much greater if the associated problem is perceived as 
serious. Problem recognition can be influenced by how problems are 




constituent feedback. Budget crises are a special consideration in 
problem recognition as they often override other problems. 
2. Policies or proposals: This stream represents the process by which 
policy proposals are created, discussed, revised, and adopted for 
serious consideration. Proposals can be attached to the same problem, 
and getting a proposal on the short list typically takes time and the 
willingness to pursue it by using many tactics. Proposals tend to be 
more successful if they are seen as technically feasible, compatible 
with decision-maker values, reasonable in cost, and appealing to the 
public. 
3. Politics: In this stream, politics are political factors that influence 
agendas, such as changes in elected officials, political climate or mood 
(e.g., conservative, tax averse), and the voices of advocacy or 
opposition groups. 
When all three streams come together, policy initiation or change is at its greatest 
(Soroka, 1999). Kingdon (1995) noted that the three streams operate parallel in a policy 
area until one or more of the streams meet in a window of opportunity that represents a 
possibility that policy may develop or change. Similarly, Soroka (1999) related that the 
combination of streams can result in a policy window due to changes in the problem or 
political streams. Windows can predictably or unpredictably appear due to events such as 




In the United States, the stem cell controversy opens a window to a larger moral 
problem (Dresser, 2010). According to Dresser (2010), the social justice inquiry about 
what justifies the United States substantial investment in biomedical innovation, when 
millions of people in the United States and abroad are denied access to proven medical 
interventions, raises questions about the priority that stem cell and other basic science 
studies should have in the competition for limited resources. Dresser argued that if 
government officials and health advocates want to help patients, meaningful help would 
also come from a system that supplied adequate health care to more people, both across 
the nation and worldwide. 
In regard to Kingdon’s (1995) three streams (problems, policies, and politics), 
problems with hESC began with the 1998 discovery, which introduced new possibilities 
(Chayabunjonglerd, 2012). Chayabunjonglerd (2012) reported that scientists sought to 
gain more funding through governmental sponsorship and argued that the Dickey-Wicker 
Amendment that banned the use of human embryos in federally funded projects hindered 
significant advances in health care. The author noted that the issue of federal funding of 
hESC research raised the important question of whether the government should and can 
fund hESC research. Chayabunjonglerd (2012) claimed that President Bush’s 
inauguration represented significant change in the political stream, which opened a policy 
window for him to push forward his solution on hESC research. This resulted in the 
policy stream, where President Bush issued a Presidential Statement in 2001 that limited 




Kingdon’s agenda-setting theory served as the theoretical foundation in 
Fukushima’s (2013) study of chemical biology as part of postgenomic research agenda. 
Specifically, Fukushima analyzed how three different levels, laboratory practices, 
community of scientists, and policy processes, are mutually important. In addition, 
Fukushima analyzed Japanese scientists’ and policy makers’ belief that chemical biology 
is important in science and policy. Findings indicated that the three levels have developed 
in parallel by joining different theoretical traditions. In addition, different elements 
beyond the laboratory and policy process facilitated or accelerated these developments: 
the character of policy entrepreneurs, the international environment, and the cultural 
mood, which promoted parallel developments.  
Dickey-Wicker Amendment 
 The amendment, authored by Representative Jay Dickey of Arkansas and Roger 
Wicker of Mississippi, was created as a response to the 1994 recommendations of the 
NIH Embryo Research Panel (the Panel; Kearl, 2015). According to Kearl (2015), the 
Panel consisted of ethicists, public policy analysts, and patient advocates who evaluated 
when and under what circumstances human embryo research should be federally funded. 
They also assessed what moral and ethical controversies would be raised by this research 
and compiled their findings in a report on September 27, 1994, titled, Report of the 
Human Embryo Research Panel. The Panel recommended that research on unused 
gametes and embryos from fertility procedures like IVF should be allowed with the 




research purposes; however, President Clinton immediately rejected this part of the 
proposal.  
Since 1996, the amendment has been attached to appropriations bills for the 
Department of Health and Human Services, Labor, and Education (Kearl, 2015). Kearl 
(2015) reported that the amendment was the response of the Republican-controlled House 
and Senate to ethical concerns surrounding federal funding for any research involving 
human embryos. Kearl related that this amendment restricts the use of federal funds for 
creating, destroying, or knowingly injuring human embryos. However, the amendment 
only prohibited federal funding for experimentation using human embryos. Thomson, 
researcher from the University of Wisconsin, created the first human stem cell line using 
private funds in 1998. As a result of Thomson’s discovery, Rabb, a lawyer at the 
Department of Health and Human Services, argued that experimentation with the lines 
derived using private funds could receive federal funding. Rabb’s legal interpretation was 
endorsed by the Clinton administration and revised guidelines were created in August 
2000 for when federal funds could be provided to researchers. However, in 2001, 
President Bush withdrew the Clinton administration’s guidelines. On March 9, 2009, 
President Obama EO 13505, Removing Barriers to Responsible Scientific Research 
Involving Human Stem Cells, lifted restrictions to federally funded stem cell research. 
Kearl noted that the amendment was renewed on March 11, 2009 in the 2009 Omnibus 
Appropriations Act, Pub. L. 188-8, and remains the only legal obstacle to the federal 




United States National Policies 
 This section discusses the United States’ stem cell policies. It is organized in the 
following subsections: United States’ stem cell policy and adoption of new policy 
guidelines.  
United States’ Stem Cell Policy 
 In this subsection, the U.S. stem cell policy will be discussed in further detail. 
According to Keiper and Levin (2010), in 1999, the Clinton administration’s Department 
of Health General Counsel noted its support to fund stem cell research with hESCs that 
were discarded, destroyed, injured, or at risk. However, the funds could not be used to 
destroy the embryos. The authors noted that the Clinton administration may have sent the 
wrong message to scientists by allowing them to destroy embryos with private funding 
and then use federal funds to conduct further research. However, President Clinton’s 
policy did not take effect because his second term ended before funds were released.  
 In 2001, the Bush administration decreased the number of hESC lines that could 
be funded by the federal government (Keiper & Levin, 2010). Keiper and Levin (2010) 
noted that further constraints were placed on stem cell development in the United States. 
Researchers were given permission to work on approximately 60 to 78 hESC lines. 
President Obama overturned President Bush’s policy on ESC research. He instructed the 
NIH to create guidelines that would allow researchers to receive federal funding while 
working on stem cell lines that were created from extra embryos frozen in IVF clinics, 




The continuous changes in the policy by each President have been a source of 
great concern for representatives of states such as California, who support hESC research 
(Adelson & Weinberg, 2010). Adelson and Weinberg (2010) related that in some states, 
additional revenue was added to the budget to further stem cell research programs. For 
example, in 2004, after President Bush’s policy denied the use of federal funds to further 
research, California officials created the California Research Cures Initiatives to continue 
with their research after law was passed to stop federal funding to support stem cell 
research and to ban those who continued their study on stem cells from using laboratories 
and facilities that were supported by federal funds. California went on to create the CIRM 
to provide oversight and created funding for all research in their state. The CIRM agreed 
to contribute $3 billion over a decade and create another $3 billion through the sale of 
public bonds and the state general fund to aid in the study of stem cells. 
Adoption of New Policy Guidelines 
Policy uncertainty affects researchers’ plans more significantly than temporary 
funding bans (Levine, 2011). In 2009, President Obama reversed previous decisions of 
his predecessor to move forward with a more vigorous program to increase stem cell 
research (Wolinsky, 2009). According to Wolinsky (2009), the policy put in place by the 
previous president has been removed, but researchers that are involved in stem cell 
research taken from human embryos are still fighting red tape and are not able to gain 
access to federal funds for ESC research. 
New guidelines for research initiatives were introduced in 2009; 9 weeks after 




Obama asked Congress to develop new legislation that would coincide with the new bill 
to support the use of federal funding since public support had increased and had been 
unprecedented in recent years. Wadman (2009) reported that while President Obama 
changed the ESC funding policies of his predecessors, U.S. Representatives Diana 
Degette of Colorado and Mike Castle of Delaware, urged Congress to support and fund 
stem cell lines, where parental permission was given for the use of embryos leftover at 
infertility clinics. Levine (2011) noted that a legal challenge, which claimed that Obama’s 
policy violated the Dickey-Wicker Amendment, was filed following the Obama 
administration’s stem cell policy and this resulted in uncertainty in the field. U.S. District 
Court Judge Royce Lamberth granted a preliminary injunction, which prevented the 
implementation of the Obama administration’s policy. However, the Obama 
administration appealed and on April 29, 2011, the U.S. Court of Appeal for the District 
of Columbia allowed the NIH to resume funding hESC research while the case 
proceeded. On July 27, 2011, Federal District Court Judge Lamberth dismissed the 
plaintiff’s suit, which was in line with decision of the U.S. Court of Appeal panel 
(Association of American Medical Colleges [AAMC], 2015a).  
There is renewed interest in stem cell research to treat numerous diseases, but 
U.S. regulations and restrictions have had a negative effect on ESC research efforts 
(Cyranoski, 2013). Cyranoski (2013) related that stem cell researchers are frustrated with 
the policy surrounding stem cells as it places universities at risk because they struggle to 
locate funding from private sources. Kington (2011) related that researchers were 




proponents of stem cell research an opportunity to become beneficiaries of hESC funding 
due to an existing patent. Therefore, this would result in insufficient funding for research 
under the established guidelines that offered financial gains to donors, where policies 
were not directly established. Biomedical scientists are struggling to continue their 
research as funds are limited and organizations have considered merging to hold on to the 
research that they have completed. 
International Communities’ Stem Cell Policies 
 Differences in national regulatory approaches have generated competition to 
implement stem cell programs that will give countries an edge in the global knowledge 
economy (Gottweis, Salter, & Waldby, 2009). Countries such as China, India, South 
Korea, and Singapore have been identified as emerging biotech powers (Wahlberg, 
2012). This section briefly examines stem cell policies in China, Singapore, UK, 
Australia, India, and Canada, who are all members of the International Stem Cell Forum 
(ISCF, 2016). The ISCF was founded in January 2003 to encourage international 
collaboration and funding support for stem cell research, with the overall aim of 
promoting global good practice and accelerating progress in this area of biomedical 
science (ISCF, 2016).  
China’s Stem Cell Policy 
 Biotechnologies such as stem cell science, genetic testing, and reproductive 
medicine are being examined by scholars (Wahlberg, 2012). The author noted that China 
has moved in an aggressive manner to become a super power in biotechnology. In a 2009 




that aggressively moves toward being recognized as a major party in the exploration of 
ESC research. China policy on ESC research is permissive, which has allowed them to be 
competitive by building an infrastructure that attracts scientist from various countries 
(Lysaght & Capps, 2012). State-led investment programs have lured young researchers 
from Europe and the United States to China (Wahlberg, 2012). In addition, Wahlberg 
(2012) claimed that political mobilization around biotechnology as a source of economic 
growth, aspiration in the global race to be the first, and biosecurity risk anxieties, have all 
been highlighted as facilitators of Asia’s rising science and technology strength.  
Singapore’s Stem Cell Policy 
 Singapore is another Asian country that has adopted research-friendly stem cell 
policies to secure a competitive edge in the global marketplace (Lysaght & Capps, 2012). 
Lysaght and Capps (2012) noted that Singapore’s approach has attracted scientists from 
other countries and has resulted in the development of local industries in stem cell 
science. Singapore’s approach included the establishment of a national funding body 
called the Agency of Science, Technology, and Research, and strategic plans to compete 
in the global bioeconomy. The strategic plans include provision of taxation incentives 
and venture capital schemes to encourage public and private partnerships as well as the 
creation of highly educated workers through the use of university scholarships and 
graduate placements under international renowned scientists. Other important strategies 
included technological infrastructure and the development of science parks and the 




United Kingdom’s Stem Cell Policy 
 The UK has in place a comprehensive regulatory framework for stem cell 
research (Small & Doherty, 2011). According to Small and Doherty (2011), the Human 
Fertilization and Embryology Authority is responsible for granting licenses for stem cell 
research. Research can only take place on embryos created in vitro; thus, embryos that 
have developed from eggs that have been fertilized outside of the body. The majority of 
embryos used in the UK for stem cell research is obtained from embryos that were 
originally created for fertility treatment, but were not used. The surplus IVF embryos 
have to be donated with parental consent for use in stem cell research. The UK made 
hESC research a priority and set aside $556 million for stem cell research (Nature Cell 
Biology, 2010). Gough (2013) related that hESC approval in the UK is based on the 
needs of the people and the policy is transparent and supported by evidence that 
demonstrates a level of critical appraisal and willingness to review and amend in light of 
progress. 
Australia’s Stem Cell Policy  
 Stem cell research conducted by Australian scientists adds knowledge to the field 
of human stem cells and the application of stem cell technologies (Australia Law Reform 
Commission, 2015). The Australian Law Reform Commission (2015) reported that 
publicly funded organizations and companies are involved in adult and ESC research in 
Australia. Waldby and Carrol (2012) related that human embryos and oocytes or eggs 
have become the focus of intense scientific research. Both are key tissues in regenerative 




instead of organ transplant. The researchers noted that “oocytes are essential elements in 
a type of stem cell research termed somatic cell nuclear transfer (SCNT), sometimes 
called therapeutic cloning” (Waldby & Carol, 2012, p. 513). Australia has a permissive 
legislation in place for SCNT, but has a conservative approach to research donation 
regulation. Australia’s Prohibition of Human Cloning for Reproduction and the 
Regulation of Human Embryo Research Amendment Act 2006 legislation allows the 
practice of SCNT. However, unlike the UK, Australia’s legislation does not allow for the 
use of animal oocytes for experimental purposes. In addition, in contrast to the United 
States, Australia’s legislation also does not permit the development of a reproductive 
oocyte market. In Australia, strict regulated gifting is used to transfer oocytes from donor 
to recipient.  
India’s Stem Cell Policy 
 India has introduced policies that are designed to improve their global competitive 
position in the stem cell research field (Mittal, 2013). Mittal (2013) reported that India 
has ethical guidelines for biomedical research that was published by the Indian Council 
for Medical Research (ICMR); however, limited boundaries for hESC research is used. 
India’s IVF clinics are noted to be an established source of embryos for research and 
foreign scientists visit these clinics for supplies. Due to negative publicity, India’s 
government announced that they would take steps to counter the international view of 
India as “an embryo surplus nation” (Mittal, 2013, p. 106). However, due to a lack of 
legal backing for the ICMR ethical guidelines for biomedical research, India’s stem cell 




powers of enforcement, only 40 of India’s 179 institutional ethics committees followed 
the principles noted in the document. 
Canada’s Stem Cell Policy 
 Canada did not have any laws, guidelines, research ethics boards, or funding 
agencies to govern stem cell research until March 2002 (Canadian Institutes of Health 
Research [CIHR], 2014). The CIRC (2014) reported that this urgent need was recognized 
and they announced guidelines for stem cell research in March 2002. The federal granting 
agencies, the CIHR, the Natural Sciences and Engineering Research Council (NSERC), 
and the Social Sciences and Humanities Research Council (SSHRC) adopted the 
measures and agreed that no stem cell research would be funded without the prior review 
and approval of the Stem Cell Oversight Committee (SCOC), which conforms the CIHR 
guidelines. Canada’s federal government also worked on legislation on assisted human 
reproduction, which included the use of human embryos for research. In March 2004, the 
Act called, Respecting Assisted Human Reproduction and Related Research, became law. 
The Act pertains to the derivation of stem cells from human embryos. With the guidelines 
in place, Canadian researchers have moved forward and remained at the forefront of their 
field while conducting their research according to explicit ethical standards.  
Bioethics and the Moral Debate 
 The ethical and moral disagreement on hESC research and the destruction of 
embryos continues between religion and science (Doerflinger, 2010). Stem cell research 
remains highly controversial as there are still unresolved questions about human cloning, 




Campbell (2012) reported that there are still concerns over the last decade that has 
generated political and public bioethical issues. Fadel (2012) discussed the issue of ethics 
in stem cell research and noted that it remains a lengthy and heated debate in the 
scientific literature, religious circles, and the political arena. The author noted that the 
debate includes the need to protect human life from the time of inception versus curing 
many debilitating diseases. 
There are 220 original hESCs (Fadel, 2012). Aznar and Navarro-Illana (2014) 
related that much of the controversy surrounding stem cells focus on pluripotent, ESCs, 
which are destroyed at 5 to 6 days old. According to Mintrom (2013), the question of 
what constitutes independent life is at the center of the debate about the use of hESCs in 
research and research-based therapies. Thus, there are questions about whether life begins 
at conception when the human egg is fertilized or at some later stage of development. In 
addition, the researcher noted that there are questions about the point in development of 
the embryo or fetus when human rights and other legal protections should be assigned. 
Thus, hESC research is controversial as consideration must be given to what counts as 
human life and who makes that decision.  
Some religious groups, such as representatives of the Roman Catholic Church and 
other Christian traditions, have argued that human life begins at conception; therefore, the 
embryo or fetus should be given the full respect and rights as a human being (Mintrom, 
2013). Therefore, destruction of the embryo is immoral (Mintrom, 2013). Fink (2008) 
found that the most restrictive stem cell laws are in countries where Roman Catholicism 




hand, Mintron (2013) reported that those who support hESC research have argued that 
eggs are often fertilized but they do not implant in the uterus. Even though a fertilized 
egg has the potential for human life, proponents argue that it cannot be considered equal 
to a human being until it has been successfully implanted in a woman’s uterus. 
Furthermore, some supporters also consider hESC research justifiable for the 
advancement of scientific knowledge.  
There is also the possibility that there might be an extensive growth in markets 
that trade human eggs (Mintrom, 2013). As a result, Mintrom (2013) noted that women 
may be incentivized to produce and sell eggs that would then be fertilized to create 
embryos for the purpose of destroying them at the blastocyst stage (5 to 7 days after 
fertilization) in order to harvest the stem cells. Withrow (2007) pointed out that trading of 
human eggs is a common response to the demands of infertile couples who want to gain 
access to donor eggs to make a baby. In treating infertility, Mintrom (2013) reported that 
more eggs are produced than are used to create viable embryos. Thus, surplus of eggs are 
stored, discarded, or donated to research. As a result, those in support of hESC research 
have argued that it is morally permissible to use surplus embryos for biomedical research 
that may save many lives. However, those who oppose hESC research do not agree with 
this argument and have argued that such research would still support the destruction of 
embryos. Levine (2011) related that due to the divisiveness of the hESC research debate 
and the history of policymaking in other morally charged areas, policy certainty will 




a result, hESC researchers should prepare for continued policy changes, legal challenges, 
and other challenges to their research. 
Embryonic Stem Cell Research 
This section discusses effective procedures that should be used when conducting 
biomedical research, ESCs in relation to regenerative medicine, and possible ways to 
improve stem cell research policy in the United States. It is organized in the following 
subsections: improvements in biomedical research, embryonic stem cell and regenerative 
medicine, and improving stem cell research in the United States. 
Improvements in Biomedical Research 
 To develop future innovations in health care and prevention, research is needed 
across a wide range of biomedical science (AAMC, 2015b). The AAMC (2015b) related 
that this includes basic and translational research, which would be used to implement 
science and comparative effectiveness research. Maintaining a valid and sound 
foundation for credible research with an enriched mission statement is needed to provide 
long-term healthcare outcomes, maintain a patient-centered environment, and minimize 
health disparities. Further, the AAMC reported that they work to ensure that integrity, 
privacy, and confidentiality remain an important part of innovation and improvement in 
research. Partners in improving research include the NIH, Agency for Healthcare 
Research and Quality (AHRQ), and the Department of Veterans Affairs (VA). 
 Another measure used to improve research is working with medical colleges and 
teaching hospitals to reduce conflict of interest and to gain insight on how effective 




information on annual aggregate data about conflict of interest systems, disclosures 
submitted by investigators to institutions, and financial conflict of interest are reported to 
the appropriate federal agency to help improve research metrics and transparency 
initiatives. The NIH developed strict policies and procedures that must be followed when 
providing quality research (National Institute of Neurological Disorders and Stroke 
[NINDS], 2014). According to NINDS (2014), several committees have been developed 
to oversee appropriate unit and site set-up for clinical trials in progress. The following 
steps are used to ensure research remains safe and ethical, and these steps often lead to 
new products and innovation for new procedures: 
1. Establish a manual of operating procedures (MOP) and ensure that clinics and 
labs use the same examination procedures.  
2. Use data analysis to track errors and omissions.  
3. Specify quality control measures.  
4. Put metrics in place to keep information confidential.  
5. Obtain a signed informed consent form.  
6. Practice due diligence for eligibility.  
7. Communicate the plan to all involved in the research process.  
8. Keep a staff roster. 
9. Implement training.  




Embryonic Stem Cell and Regenerative Medicine  
 The study of regenerative medicine has been around for more than 20 years 
(Mason & Manzotti, 2010). Mason and Manzotti (2010) reported that the cell-based 
therapy industry has manufactured over 675,000 units of therapy and cured more than 
323,000 patients. The CIRM (2015b) discussed the potential of stem cells to treat many 
diseases. The CIRM reported that in stem cell transplant, ESCs are specialized into the 
necessary adult cell type and those mature cells replace damage tissue that is diseased or 
injured. Other types of treatment include the replacing of neurons damaged due to a 
spinal cord injury, stroke, Alzheimer’s disease, and Parkinson’s disease or other 
neurological problems. In addition, this type of treatment could be used to produce 
insulin to treat people with diabetes and heart muscle cells after a heart attack. 
Furthermore, studying stem cells could help in understanding how to induce heart muscle 
to repair itself after a heart attack as well as studying disease, identifying new drugs, or 
screening drugs for toxic side effects. Thus, there is the potential for researchers to make 
breakthroughs in any disease. Clinical trials for ESC-based therapies are currently 
underway. 
Improving Stem Cell Research in the United States 
Although the controversy over embryo destruction continues, two developments 
have helped the proponents’ public debate over hESC research (Hyun, 2010). Hyun 
(2010) related that first is the creation of human induced pluripotent stem (iPS) cells, 
which are genetically engineered to act like hESCs and second is the Obama 




main bioethical considerations now focuses more on how stem cell research should be 
conducted instead of whether it should be conducted. Those who oppose hESC research 
applauded the iPS cell revolution, which they hoped would end ESC research. However, 
most stem cell researchers believe that iPS or other alternative source of stem cells do not 
take away the need for ongoing hESC research.  
Summary and Conclusions 
Scientists have noted the potential of stems cells to treat a wide range of diseases, 
such as spinal cord injury, stoke, Alzheimer’s disease, and Parkinson’s disease (CIRM, 
2015b). Liberal stem cell policies in many countries, such as in the UK, China, Japan, 
Belgium, and Sweden, have resulted in these countries making further progress in hESC 
research by producing more stem cell lines (Nature Cell Biology, 2010). On the other 
hand, policy uncertainty has affected hESC in the United States (Levine, 2011). As a 
result, Levine (2011) recommended that lawmakers who are supportive of hESC research 
should work to create policies that reduce the uncertainty facing stem cell scientists. 
Nature Cell Biology (2010) related that each state government will create restrictive 
policies for stem cell research within their borders, where several states have already 
done so, but a liberal policy at the federal level also softens the tone of hESC debate and 
promote greater acceptance of such research within the United States. As a result, from a 
policy perspective, more remains to be done to ensure that stem cell research flourishes in 
the United States.  
Due to the problem that federal support and funding for hESC research in the 




the debate over hESC research, and the continually evolving federal policies that have 
further hindered research efforts (Levine, 2011; Mintron, 2013; Nature Cell Biology, 
2010), in this phenomenological research study, I explored the perceptions of stem cell 
researchers, stakeholders, and investors in the United States about the effects of the 
current federal stem cell policy on stem cell research in the United States. I also explored 
the moral disagreement with stem cell research and participants’ recommendations to 
improve stem cell research policy in the United States. Rogers’s (1962) DOI theory and 
Kingdon’s (1995) agenda-setting theory served as the theoretical foundation of this study. 
Dresser (2010) related that the debate over stem cell research offers an opportunity to 
examine a variety of ethical and policy issues raised by biomedical innovation. 
Kingdon’s problem, policy, and politics streams, plus the opening of the policy window, 
resulted in the issue of public funding for hESC being placed on the decision agenda. 
Thus, the possibility of change is at its greatest when all three streams come together 
(Soroka, 1999).  
In Chapter 2, I included the introduction, literature search strategy, theoretical 
foundation, Dickey-Wicker Amendment, United States national policies, international 
communities’ stem cell policies, bioethics and the moral debate, embryonic stem cell 
research, and a summary and conclusions. In Chapter 3, I include the introduction, 
research design and rationale, role of the researcher, methodology, issues of 
trustworthiness, and a summary. In Chapter 4, I include the introduction, setting, 




summary. In Chapter 5, I include the introduction, interpretation of findings, limitations 




Chapter 3: Research Method 
In this study, seven U.S. stem cell researchers’, seven U.S. stakeholders’, and 
seven U.S. investors’ perceptions were explored about the effects of the current federal 
stem cell policy on stem cell research in the United States, the moral disagreement with 
stem cell research, and recommendations to improve stem cell research policy in the 
United States. Using snowball sampling, I collected data using telephonic semistructured 
interviews. Transcribed interview data were managed with NVivo, and data were 
analyzed using Attride-Stirling’s (2001) six steps of thematic coding. The study was 
conducted in accordance with the parameters established by Walden University’s IRB to 
ensure the ethical protection of participants. The IRB approval number was 06-16-16-
0073123. Chapter 3 includes the research design and rationale, role of the researcher, 
methodology, issues of trustworthiness, and a summary. 
Research Design and Rationale 
This section contains the research questions and phenomenological design 
rationale. 
Research Questions 
To explore the perceptions of 21 U.S. stem cell researchers, stakeholders, and 
investors about the effects of the current federal stem cell policy on stem cell research in 
the United States, the moral disagreement with stem cell research, and recommendations 





1. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the effects of the current federal stem cell policy on stem cell research 
in the United States? 
2. What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the moral disagreement with stem cell research? 
3. What do U.S. stem cell researchers, stakeholders, and investors recommend to 
improve stem cell research policy in the United States? 
Phenomenological Research Design Rationale 
A phenomenological design was used to explore stem cell researchers’, 
stakeholders’, and investors’ perceptions. Through the use of this design, the meaning, 
structure, and essence (Dalberg, 2006) of participants’ experiences in dealing with policy 
issues around stem cell research were examined. Purposive sampling, specifically 
snowball sampling, was used to collect data through in-depth semistructured interviews 
with 21 stem cell researchers, stakeholders, and investors in the United States. Data were 
analyzed using Attride-Stirling’s (2001) six steps of thematic coding.  
A quantitative research method was not used for this study because subjective 
behaviors, beliefs, and opinions cannot be measured with standardized instruments. 
Instead, a qualitative research method was used because it allowed for the understanding 
of the complex and holistic picture of participants’ experiences. Patton (2002) reported 
that qualitative research is used to explore and understand social conditions or problems 
faced by individuals and groups. In this study, the qualitative research method was used 




United States, the moral disagreement with stem cell research, and recommendations to 
improve stem cell research policy in the United States. 
Five qualitative designs considered for this study included narrative research, 
phenomenology, grounded theory, ethnography, and case study (McCaslin & Scott, 
2003). After an extensive review of the five designs, I chose the phenomenological 
design. Phenomenological research designs are used when the researcher is trying to 
understand the essence of experiences about a phenomenon (Moustakas, 1994), such as 
the current federal stem cell policy on stem cell research in the United States. Moustakas 
(1994) reported that the use of a phenomenological design help researchers to gain a 
unified vision of the essence of a phenomenon or experience.  
Role of the Researcher 
I served as a participant-observer during the in-depth semistructured interviews. I 
had direct contact with participants as I recruited them by e-mail and telephone. I 
collected interview data, which I transcribed, coded, analyzed, and interpreted. No 
personal or professional relationships existed between research participants and me. 
Therefore, I had no power over potential participants, and they participated without 
feeling coerced or obligated to take part in the study. In addition, I had no bias against 
potential participants, and I respected their rights and did not exploit them. All 
participants’ perceptions were considered, and there were no conflicts of interest in the 
study. Upon successful completion of this study, I will e-mail each participant a summary 





This section contains the following subsections: participant selection and 
sampling strategy, instrumentation and data collection, procedures, and data analysis 
plan. 
Participant Selection and Sampling Strategy 
Snowball sampling is a subset of purposive sampling, where the researcher begins 
by identifying someone who meets the criteria for inclusion in the study and then asks the 
individual to recommend others whom they know meet the study’s criteria (Trochim, 
2006a). Snowball sampling was used to identify participants with expertise in the field of 
stem cell research. Seven stem cell researchers, seven stem cell stakeholders, and seven 
stem cell investors in the United States were used in the study. Mason (2010) reported 
that the sample size in qualitative studies is normally small in comparison to quantitative 
studies. For phenomenological studies, Klenke (2008) reported that the sample size might 
range from two to 25 participants, while Morse (1994) recommended at least six. For the 
current study, 21 participants were used to explore experiences regarding stem cell 
research. Saturation is the point in data collection when the collection of new data does 
not shed any further light on the issue under investigation (Glaser, Strauss, & Strutzel, 
1968). The relationship between saturation and sample size was sufficient in this study 
because through the use of snowball sampling, I included 21 participants to obtain the 
richest data possible. Saturation was reached with 21 participants. Potential participants 
were recruited using the snowball sampling strategy, and included 122 men and women 




government organization, private company, or university; a stem cell stakeholder who 
was a faculty member at a university where stem cell research was being conducted; or 
an investor who worked for a government organization or private company that invested 
in stem cell research in the United States. Potential participants were sent an invitation 
letter to participate in the study and were asked to recommend other stem cell 
researchers, stakeholders, or investors who met the selection criteria (see Appendix A). 
Instrumentation and Data Collection 
I used a 45-minute researcher-developed interview questionnaire to collect data 
about perceptions of stem cell research in the United States. The questionnaire was 
structured to elicit stem cell researchers’, stakeholders’, and investors’ perceptions about 
the effects of the current federal stem cell policy on stem cell research in the United 
States and the moral disagreement with stem cell research. Additionally, participants 
were asked about their recommendations to improve stem cell research policy in the 
United States. The interview guide contained an introduction, welcome, discussion 
purpose, discussion guidelines, general instructions, possible probes, interviews 
questions, and a conclusion (see Appendix B). The interview questions were open ended 
to provide for a deep exploration of the stem cell topic. Through the use of open-ended 
questions, participants were able to provide detail, and I was able to probe deeper to gain 
a better understanding of the responses (see Turner, 2010).  
Procedures 
I completed the NIH Office of Extramural Research Human Research Protections 




the Georgia Department of Public Health’s (2015) directive to obtain legal informed 
consent from potential participants or their legal representative prior to their participation 
in the study. After I received Walden University’s IRB approval to conduct the study, I 
contacted potential participants by e-mail or telephone who were known to meet the 
selection criteria. Contact information for stem cell researchers, stakeholders, and 
investors was obtained from personal contacts and public information available online. I 
did not include anyone with whom I had a personal relationship, including family 
members, friends, coworkers, or professional and personal associates, to prevent 
perceived coercion to participate. I asked professional and personal associates if they 
knew individuals who met the study’s criteria to get snowball sampling going. I also used 
public information available online through organizations such as Microbot Medical Inc. 
(2017) and Cell Therapy Foundation (2014) to obtain information about those involved in 
stem cell research. I looked up their public contact information from individual 
companies’ websites. I also used the NIH (2015c) stem cell information about 
organizations, advocacy groups, professional associations, federal government sites, and 
others involved in stem cell research. I reviewed those resources and found public contact 
information for potential participants. 
I sent potential participants an invitation letter and asked them to recommend 
other stem cell researchers, stakeholders, or investors who met the selection criteria by 
providing their personal contact information or public work contact information, but not 
their nonpublic work contact information (see Appendix A). Participants were informed 




participants were asked to complete the questions on the invitation letter and e-mail them 
back to me if they were interested in participating in the study. Their responses to the 
questions helped me ensure that they met the selection criteria. Once I received the e-mail 
responses to the questions asked on the invitation letter, I e-mailed prospective 
participants the consent form and requested their consent by asking them to reply to the 
e-mail with the words “I consent.” Participants were also informed that they could ask 
questions before giving their consent and at any time during the interview process.  
Once participants gave their consent, I contacted them by telephone or e-mail to 
set up an appointment to conduct individual semistructured interviews by telephone at a 
time that was convenient for them. Telephonic interviews were conducted because some 
participants resided in different states. Interviews were audio-taped and took 
approximately 45 minutes (see Appendix B). Before concluding the telephonic 
interviews, I asked participants if they had any questions or concerns. After all questions 
or concerns were addressed, I concluded the interviews and thanked participants for their 
participation. It was unlikely that participation would arouse discomfort; however, I 
provided participants with reasonable protection from psychological distress by 
informing them that they could seek counseling by calling the Substance Abuse and 
Mental Health Services Administration’s (SAMHSA’s, 2014) national helpline at 1-800-
662-4357 should they experience any negative effects from taking part in this study. 
After the interviews were transcribed, I e-mailed each transcript to the participant 
to review for accuracy. Transcription review is a quality control process that ensures the 




Cole, 2012). I discussed the participants’ feedback with them by telephone. The 
transcription review process took approximately 20 minutes. Once this study is 
completed, I will e-mail a summary report of the research findings to each participant. 
Data will be secured in a locked file cabinet and password-protected computer in my 
private home office. I am the only one with access to the records. Data will be kept for a 
period of at least 5 years, as required by Walden University. After that period, data will 
be properly destroyed using techniques such as shredding and demagnetizing. 
Data Analysis Plan 
To analyze the interview questions, I transcribed the interviews using WebEx 
audio playback. I then transferred the transcripts to NVivo analysis software, which 
assisted in managing the data. The next step was to analyze the data using the Attride-
Stirling’s method (2001), which outlines six steps or stages of thematic coding, which is 
discussed in further detail below. NVivo is a software program designed to facilitate 
qualitative data analysis (Zamawe, 2015). NVivo provided a way to manage and organize 
the interview transcripts so that I could logically identify thematic phrasing. NVivo 
allows the researcher to upload files such as transcripts, select parts of the document, and 
label them with particular descriptions (Zamawe, 2015). NVivo also produces word 
frequency counts, charts of the labels that are used most often, and text searches 
(Zamawe, 2015). The labels can be organized into categories, notes can be made about 
links between labels and concepts, and relationships can be created between labels and 
documents (Zamawe, 2015). Finally, for the results sections, tables can be created to 




Coding and categorization of interview transcripts facilitated thematic analysis of 
the interview data. I followed Attride-Stirling’s (2001) six steps on how to conduct a 
thematic analysis and the steps are modified to properly fit this specific research study’s 
methodology: 
1. Analysis stage A: The reduction or breakdown of text: Step 1. Coding of 
material: (a) devised a coding framework and (b) dissected or divided text into 
text segments using the coding framework in Step 1a. Step 2. Identifying of 
themes: (a) abstracted themes from coded text segments and (b) refined and 
edited themes. Step 3. Constructing of thematic networks: (a) arranged 
themes, (b) selected codes or the other essential perceptions of the 
participants, (c) rearranged into themes and codes (with the themes as the ones 
with the highest responses and the codes as the ones that followed), (d) 
illustrated as thematic networks or groups, and (e) verified and refined the 
networks. 
2. Analysis stage B: Exploration of text: Step 4. Described and explored 
thematic networks or groups: (a) described the network or group and (b) 
explored the network or group. Step 5. Summarized thematic networks or 
groups. 
3. Analysis stage C: Integration of exploration: Step 6. Interpreted the patterns.  
4. During data analysis, I found no discrepant cases. Themes and subthemes 
emerged during the data analysis process, which are discussed later in the 




I found no discrepant cases during data analysis. Themes and subthemes emerged 
during the data analysis process, which are discussed later in the results section in 
Chapter 4. Preliminary themes included ethical concerns, religious influence, funding 
shortages, end use of stem cells, and concerns about NIH guidelines. Table 2 in Chapter 4 
provides the theories, preliminary themes, and subthemes based on my literature review 
and theoretical frameworks, which served as a starting point of my data analysis. 
Issues of Trustworthiness 
Qualitative research has richness to it and as such, data must be coded and 
interpreted correctly during the collection and evaluation process to ensure a level of 
trustworthiness (Moretti et al., 2011). This section is organized in the following 
subsections: validity and reliability of qualitative data and ethical procedures. 
Validity and Reliability of Qualitative Data 
 In this qualitative phenomenological study, validity and reliability were 
established through credibility, transferability, dependability, and confirmability. 
According to Shenton (2004), credibility or internal validity is one of the most important 
factors in establishing trustworthiness and refers to how congruent the findings are with 
reality. In this study, credibility was established through transcription reviews. I e-mailed 
each participant the transcript of the interview and asked that they review the transcript 
for accuracy. I discussed participants’ feedback with them by telephone or e-mail.  
Transferability or external validity refers to the extent to which the study’s 
findings can be applied to other situations (Shenton, 2004). Findings from this study 




United States who have had similar experiences. Merriam (2009) noted that rich, thick 
description in reference to the setting, the participants, and the findings of the study is 
one strategy that can be used to establish transferability. It is also the responsibility of the 
qualitative researcher to describe the context of the study and its participants in detail so 
that the possibility of replication exists. Hence, I provided a rich, thick description of the 
context of the study and the participants. I also supported the findings of this study 
through the use of direct quotes and summaries of participants’ interview responses. 
Dependability is the qualitative counterpart to reliability. According to Shenton 
(2004), the study’s processes should be reported in detail, which enables future 
researchers to repeat the work. However, this does not necessarily mean that same result 
will be obtained. In this study, dependability was established through audit trails, which 
involves a thorough collection of documentation for all aspects of the research (Rodgers, 
2008). Documentation that were used in this study included tape recorded interviews, 
transcriptions of those interviews, and transcription reviews; thus, data were 
authenticated by comparing these forms of data.  
Confirmability is the qualitative counterpart to objectivity. Trochim (2006b) 
reported that confirmability is the degree to which the research results can be confirmed 
or corroborated by other researchers. Therefore, I ensured that the data and interpretations 
of the findings were not a figment of my imagination, but were clearly derived from the 
data (Tobin & Begley, 2004). In addition, I established confirmability through reflexivity, 
which is the process of reflecting critically on the self as researcher (Merriam, 2009). I 




effects of the current federal stem cell policy on stem cell research in the United States, 
the moral disagreement with stem cell research, and recommended ways to improve stem 
cell research policy in the United States. 
Ethical Procedures 
 The NIH human research protection training was completed (see Appendix C). I 
also complied with all federal and state regulations. The study was also conducted in 
accordance with the parameters established by Walden University’s IRB to ensure the 
ethical protection of research participants. The data I collected present no greater than 
minimal risk and I followed Walden University’s IRB guidelines to protect the data that 
were generated from the interview questions, such as the interview recordings and the 
transcriptions.  
 Before data collection began, all participants were e-mailed a consent form that 
had been approved by the Walden University IRB; thus, obtaining their permission to 
participate in the study. The consent form outlined participants’ protections and ethical 
guidelines that were followed during the research study. These guidelines included the 
voluntary nature of the study and participants’ right to withdraw at any time without fear 
of reprisal or penalty. The consent form also outlined any physical or psychological risks 
that participants might experience and indicated that participants were not obligated to 
complete any part of the study with which they were not comfortable. It was unlikely that 
participation in this study aroused any acute discomfort; however, participants were 
referred to the SAMHSA’s national helpline at 1-800-662-4357 if they experienced any 




 Participants were provided with my contact information and the contact 
information for my Dissertation Committee Chair in the event that they had any further 
questions or concerns about the research. Participants were provided with the contact 
information of the Walden University representative with whom they could talk privately 
about their rights as participants. I respected all participants during the research process 
and data collection stage. After data were collected, all identifiable data were eliminated; 
therefore, the interviews were numbered or coded to match the participant. This protected 
participants’ identities; however, I knew the identity of the participants. Thus, all 
participants’ identity were kept confidential.  
 Participants were informed that the interviews would be audio-taped and that a 
verbatim transcription would be made and analyzed later. I have kept all audio-recorded 
data secured, which I transcribed. Only my supervising committee had access to the data. 
All data are kept in a locked file cabinet and password protected computer in my personal 
home office for at least 5 years, as required by Walden University. Data will be properly 
destroyed after that time period using methods such as shredding and demagnetizing. 
Once this study is completed successfully, a summary report of the research findings will 
be e-mailed to each participant.  
Summary 
 In this study, seven U.S. stem cell researchers’, seven U.S. stakeholders’, and 
seven U.S. investors’ perceptions were explored about the effects of the current federal 
stem cell policy on stem cell research in the United States, the moral disagreement with 




United States. The in-depth semistructured interviews were transcribed and transcriptions 
were analyzed. Common words or phrases were grouped and labeled for coding across 
categories of inquiry. Once data were grouped, subsets were compared and contrasted. 
This allowed for the search of related codes and the making of inferences about these 
connections or patterns. 
In Chapter 3, I included the introduction, research design and rationale, role of the 
researcher, methodology, issues of trustworthiness, and a summary. In Chapter 4, I 
include the introduction, setting, demographics, data collection, data analysis, evidence of 
trustworthiness, results, and a summary. In Chapter 5, I include the introduction, 





Chapter 4: Results  
The purpose of this qualitative phenomenological study was to explore the 
perceptions of 21 U.S. stem cell researchers, stakeholders, and investors about the effects 
of the current federal stem cell policy on stem cell research in the United States, the 
moral disagreement with stem cell research, and recommendations to improve stem cell 
research policy in the United States. I conducted in-depth telephonic semistructured 
interviews with 21 stem cell researchers, stakeholders, and investors in the United States 
to answer three research questions: (a) What are U.S. stem cell researchers’, 
stakeholders’, and investors’ perceptions about the effects of the current federal stem cell 
policy on stem cell research in the United States; (b) what are U.S. stem cell researchers’, 
stakeholders’, and investors’ perceptions about the moral disagreement with stem cell 
research; and (c) what do U.S. stem cell researchers, stakeholders, and investors 
recommend to improve stem cell research policy in the United States? The interview 
transcripts were analyzed using Attride-Stirling’s (2001) six steps of thematic analysis. In 
Chapter 4, I present themes according to their respective research questions. I also 
include the setting, participant demographics, data collection, data analysis, evidence of 
trustworthiness, and a summary. 
Setting 
I used snowball sampling in the Southeast, Northeast, Midwest, and West Coast 
regions of the United States. Telephonic interviews took place from July 6, 2016 to 




have influenced participants’ experiences at the time of the study or that may have 
influenced my analysis of the data.  
Demographics 
From the 43 researchers, 47 stakeholders, and 32 investors who were initially 
contacted, I chose seven stem cell researchers, seven stem cell stakeholders, and seven 
stem cell investors in the United States to participate in the study. Thirteen out of 21 
participants (62%) were female, and eight out of 21 participants (38%) were male. Stem 
cell researchers worked at a private company or university, stem cell stakeholders were 
faculty members at a univeristy where stem cell research was being conducted, and stem 
cell investors worked for a government organization or private company that invested in 
stem cell research in the United States. Eight female participants worked in the private 
sector, four at a university, and one in the government. Two male participants worked in 
the private sector, four at a university, and two in the government. Six female participants 
were researchers, four were investors, and three were stakeholders. One male participant 
was a researcher, three were investors, and four were stakeholders. The participant 








Classification Work sector Acronym 
1 Female Researcher Private FRP 
2 Male Investor Government MIG 
3 Male Stakeholder University MSU 
4 Male Researcher Private MRP 
5 Male Investor Government MIG 
6 Female Investor Private FIP 
7 Male Stakeholder University MSU 
8 Female Investor Private FIP 
9 Female Stakeholder University FSU 
10 Female Investor Private FIP 
11 Female Stakeholder University FSU 
12 Male Stakeholder University MSU 
13 Female Researcher University FRP 
14 Female Investor Government FIG 
15 Female Stakeholder University FSU 
16 Female Researcher Private FRP 
17 Female Researcher Private FRP 
18 Female Researcher Private FRP 
19 Female Researcher Private FPR 
20 Male Stakeholder University MSU 
21 Male Investor Private MIP 
 
Data Collection 
I developed an interview guide to collect data about participants’ perceptions of 
stem cell research in the United States. The interview questions were used to explore 
participants’ perceptions of (a) the effects of the current federal stem cell policy on stem 
cell research in the United States; (b) the NIH ethical policies regarding human ESC 
research and their effect on stem cell research in the United States; (c) whether U.S. stem 




(d) how the Dickey-Wicker Amendment restricts the use of federal funds for creating, 
destroying, or knowingly injuring human embryos; (e) how the U.S. stem cell policy has 
diminished or improved U.S. stem cell research competitiveness with other countries; (f) 
how the U.S. can become more competitive with other countries that they lag behind in 
relation to stem cell research; (g) the moral disagreement with stem cell research; (h) how 
stem cell proponents and opponents can compromise on stem cell research; and (i) 
recommendations to improve stem cell research policy in the United States. Interviews 
were audio-taped and took approximately 45 minutes. After the interviews were 
transcribed, I e-mailed each participant the transcript and asked him or her to review it for 
accuracy. The transcription review process took approximately 20 minutes. I incorporated 
participants’ feedback in the transcriptions, and no participants’ feedback altered the 
original responses in any way. 
Data Analysis 
 Recorded interviews were transcribed, data were managed with NVivo, and data 
were analyzed using Attride-Stirling’s (2001) six steps of thematic analysis. The steps 
were modified to fit the current study’s methodology. Table 2 depicts the preliminary 
themes and subthemes that served as a starting point for the data analysis, along with 





Theoretical Origins of Preliminary Themes and Subthemes  
Theories Preliminary themes Subthemes 
Agenda-setting theory Policy stream • NIH guidelines 
• Dickey-Wicker 
Amendment 
• Political orientation of 
the executive branch 
• Political orientation of 
the legislature 
 
Agenda-setting theory Politics stream • Ethical considerations 
• Religious influences 




Diffusion of innovations Persuasion stage • Religious influences 
• Medical value of 
research 
• Misconceptions about 
research, including 
perceived link to 
abortion 
 
Diffusion of innovations Knowledge stage • Shifts in public 
perception 








1. Analysis Stage A: The reduction or breakdown of text. In Step 1, I devised a 
coding framework and dissected or divided text into text segments using the 
coding framework. In Step 2, I abstracted themes from coded text segments 
and refined and edited themes. In Step 3, I arranged themes, selected codes or 
other essential perceptions of the participants, rearranged codes into themes 
(with the themes as the ones with the highest responses and the codes as the 
ones that followed), illustrated as thematic networks or groups, and verified 
and refined the networks. 
2. Analysis Stage B: Exploration of text. In Step 4, I described the network or 
group and explored the network or group. In Step 5, I summarized thematic 
networks or groups. 
3. Analysis Stage C: Integration of exploration. In Step 6, I interpreted the 
patterns.  
During the data analysis phase, no discrepant data were found. Table 3 presents 
the number and percentages of the themes that emerged during data analysis in relation to 
stem cell researchers’, stakeholders’, and investors’ perceptions. Number of occurrences 
refers to the number of times a theme occurred in the interview transcripts. Percent of 
occurrences is the total number of occurrences of the theme divided by the total number 





Theme Occurrences and Percentages for Stem Cell Researchers’, Stakeholders’, and 
Investors’ Perceptions 
Themes No. of occurrences % of occurrences 
Perceptions of federal 
policy 
142 65% 
Perceptions of moral 
disagreement 
44 20% 
Policy recommendations 34 15% 
Total 220 100% 
 
Evidence of Trustworthiness 
In this qualitative phenomenological study, I established validity and reliability 
through credibility, transferability, dependability, and confirmability. I established 
credibility through transcript reviews. I e-mailed each participant the transcript of the 
interview and asked that he or she review the transcript for accuracy. I discussed 
participants’ feedback with them by telephone or e-mail. I ensured transferability by 
providing a rich, thick description of the context of the study and the participants. I also 
supported the findings of this study through direct quotes and summaries of participants’ 
interview responses. I established dependability through the use of audit trails, where I 
included documentation for all aspects of the study. Documentation included tape-
recorded interviews, transcripts of interviews, and transcript reviews; data were 
authenticated by comparing these documents. I established confirmability by ensuring 
that the data and interpretations of the findings were not a figment of my imagination, but 




reflexivity by reflecting on any biases that I had about the effects of the current federal 
stem cell policy on stem cell research in the United States, the moral disagreement with 
stem cell research, and recommended ways to improve stem cell research policy in the 
United States.  
Results 
Based on the data analysis, three overarching themes and 14 subthemes emerged. 
The research questions served as the basis for each overarching theme. Thematic analysis 
Step 1 or categorization of text appears in Appendix D, which shows all of the 
participants’ responses that corresponded with each overarching theme and subtheme. In 
the following section, the themes and subthemes are presented according to their 
corresponding research question. 
Research Question 1 
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the effects of the current federal stem cell policy on stem cell research in the United 
States? One overarching theme and five subthemes emerged to answer this research 
question. Participants’ perceptions of U.S. federal stem cell policy varied widely. Some 
participants perceived the policy as beneficial, others perceived it as irrelevant, and some 
perceived it as a constraint on stem cell research. Participants who perceived the federal 
stem cell policy as beneficial to U.S. stem cell research expressed their approval, stating 
that the Obama administration’s comparatively relaxed funding policy was more 
advantageous to stem cell researchers than the Bush administration’s restrictions, 




participants reported that funding restrictions, which only affected research conducted on 
hESCs, had lost much of their significance with the increasing prevalence of research 
involving iPS cells and adult stem cells. Six participants (29%) indicated that current 
funding restrictions prescribed by the Dickey-Wicker Amendment were invalidated by 
their reliance on justifications that were perceived as irrational, and 13 participants (62%) 
agreed with the amendment. Almost all participants, however, agreed with the NIH 
ethical policy, with 17 of the 21 participants (81%) describing the policy as a valuable 
means of promoting ethical science.  
In regard to the context of each research setting, 92% of all participants believed 
that the Obama administration’s more relaxed stem cell policy was as a positive step in 
the right direction. Researchers’ perception on the effects of the Obama administration’s 
federal stem cell policy is that it is restrictive but they are moving forward by doing 
research in other countries, using less hESC research, and engaging more in adult stem 
cell research. Investors’ and stakeholders’ perceptions were closely aligned in how they 
perceived the Obama administration policy, where they noted that it is not very 
restrictive, but federal funding on new lines of hESC research is still restrictive; thus, 
research can continue with private donations. Most researchers agreed with the NIH 
policy as they understood the need for strict supervision. Five of the seven investors 
(71%) agreed with the NIH policy and noted that it was necessary to protect donors, 
while three out of seven stakeholders (43%) agreed with the NIH policy. Researchers, 
investors, and stakeholders who did not agree with the NIH policy described the policy as 




cells and their uses for research. Stakeholder and investors who disagreed with the 
Dickey-Wicker Amendment described it as a religious agenda. On the other hand, 
researchers discussed the limited scope of the amendment, but emphasized the 
legislation’s negative effect on research. Participants agreed that stem cell policy changes 
from each administration made it challenging to compete with other countries. 
Researchers emphasized that the best way to be more competitive was to educate people, 
increase funding, and do more clinical trials. Table 4 depicts the occurrences and 
percentages for perceptions of the effects of Obama administration’s federal stem cell 
policy theme and subthemes. 
Theme 1: Perceptions of the effects of the Obama administration’s federal 
stem cell policy. This theme has five subthemes, which are as follows: (a) overall 
perceptions; (b) perceptions of the Obama administration’s funding policy, which is the 
policy that was created to inform applicants and grantees of the conditions that must be 
met in order for the NIH to fund stem cell research; (c) perceptions of the NIH’s ethical 
policy, which was developed based on President Obama’s EO 13505 to ensure 
researchers were informed of the new processes needed to conduct human stem cell 
research; (d) perceptions of the Dickey-Wicker Amendment, is an amendment attached to 
the appropriation bills ensuring that no federal funds get used for creating, destroying or 
knowingly injuring human embryos; and (e) perceptions of competition between the 
United States and other countries. Participants’ responses are categorized in the five 





Subtheme Occurrences and Percentages for Perceptions of the Effects of Current Federal 
Stem Cell Policy  
Theme Subthemes No. of occurrences % of occurrences 
Perceptions of the 
effects of the 










































Subtheme 1: Overall perceptions. Participants’ perceptions of U.S. federal policy 
on stem cell research varied considerably. Only a few participants expressed approval of 
the Obama administrations’ policy. Participant 12 (MSU) stated, “I do believe the current 
federal policy is for the betterment of science research and will have positive long-term 
effects on disease and disease treatment.” Participant 13 (FRU) discussed the difference 
between the policies of the Bush and Obama administrations, noting that the “current 
federal stem cell policy has certainly boosted stem cell research considerably over the last 
7 years.” Participant 13 also stated: 
[The Obama administration’s policy] has allowed stem cell researchers more 
flexibility in choosing cell lines of interest. In addition, there has been more 




being achieved in stem cell research in the United States. Importantly, multiple 
clinical trials have been initiated for stem cell therapy of degenerative diseases.  
Participant 21 (MIP) indicated that the current stem cell policy is permissive 
because it does not limit scientists’ abilities to address interesting and important 
questions. On the other hand, Participant 7 (MSU) related that despite the thoughtfulness 
of the current stem cell policy, it is still restrictive in terms of access to carry out 
research. Participant 6 (FIP) related that while the current stem cell policy makes it easier 
to do more research, funding is still slow due to past policies and restrictions. Participants 
1, 14, 15, and 20 described the policy as a significant constraint. Participant 1 (FRP) 
noted that despite all the testing that is taking place, the benefit from stem cell is still not 
fully realized. Participant 14 (FIG) pointed out that restrictive policies could have a 
negative effect on the international standing of U.S. stem cell research because major 
research companies move their stem cell research division to “other countries where 
scientists are permitted to conduct research without any restriction.” Participant 15 (FSU) 
perceived the policy as negatively affecting medical research due to limiting ESC 
research as well as rapid advancement in therapeutic approaches and applications. 
Participant 15 also noted that the federal stem cell policy does not affect her research and 
that progress has been made despite how strict the policy may be. Similarly, Participants 
15 and 20 reported that while the policy does limit ongoing research, its effects are 
limited due to the use of iPS cells and some researchers have moved to countries where 




 Similarly, Participant 16 (FRP) related that there may be limits on what research 
can be carried out using ESCs with federal funds, but most research is concentrated on 
the use of adult stems in the United States. Other part participants described the effects of 
the federal policy on stem cell research as limited or negligible, such as Participant 10 
(FIP) who noted that the current research that she is a part of is not affected by federal or 
state regulations because they are using iPS cells, which are generated from fibroblasts 
donated by patients. Similar to Participant 10, Participant 11(FSU) shared that 
government restrictions are less of a concern as researchers increasingly include adult-
derived stem cells and iPSCs. Participant 11 further shared that few of her “colleagues 
are performing research with ESCs, though this may change concurrently with changes in 
policy.” Participants 3, 18, and 19 also discussed the use of adult-derived stem cells as a 
viable alternative to ESCs. Participant 3 (MSU) related that the federal stem cell policy is 
not very restrictive since researchers can use ESC lines as well as adult-derived stem 
cells. In addition, Participant 3 noted that ESCs can be derived from nonhumans as well 
as from skin cells. Participant 18 (FRP) and participant 19 (FRP) related that the policy 
does not have an effect or is an issue as research is more inclusive of adult stem cells in 
contrast to ESCs. 
While Participant 17 (FSU) also noted the limited effects that the stem cell policy 
has on research, Participant 15 pointed out a way in which federal restrictions might have 
a negative effect on research despite the variety of alternatives to hESCs. Participant 15 
stated, “[Federal policy] does not allow us to compare data generated from adult versus 




Participant 8 (FIP) related that that federal policy restrictions related only to federal 
funding of research in certain areas and that alternative funding sources were available to 
researchers who wanted to work in those areas: 
If you mean the ban on federal funding for embryonic research put in place during 
the Bush administration and lifted during the Obama administration, it only 
banned the use of taxpayer dollars to pay for embryonic research. Taxpayer 
dollars have always been a significant source of funding for adult stem cell 
research and now iPS cell research. The ban only meant that if you wanted to do 
ESC research, you’d have to get private grants or venture capital to cover the 
costs. ESC research continued in labs across the country, but was largely 
leapfrogged by the discovery of iPS cells in 2012.  
 Subtheme 2: Perceptions of the Obama administration’s funding policy. On 
March 9, 2009, President Obama issued EO 13505, Removing Barriers to Responsible 
Scientific Research Involving Human Stem Cells, with the goal of strengthening hESC 
research in the United States (Levine, 2011; Nature Cell Biology, 2010). The Secretary of 
Health and Human Services, through the Director of the NIH, may support and conduct 
responsible, scientifically worthy human stem cell research, including hESC research, to 
the extent permitted by law (Obama, 2009). However, President Obama’s new stem cell 
policy did not approve the 21 hESC lines that were eligible under the Bush administration 
(Levine, 2011). Participants’ perceptions of the Obama administration’s policy fell into 
two broad categories, which are as follows: (a) Some participants believed that the 




been rendered partially or completely ineffective due to contextual factors. Some 
participants perceived the policy as having positive effects and cited significant 
advancements in knowledge that were attributed to President Obama’s executive order. 
Participant 13 (FRU) stated: 
Significant progress has been made in stem cell research over the last 7 plus years 
and we are at the cusp of realization of its clinical potential. In addition, there has 
been a great push for using stem cell as disease models and for in vitro toxicity 
testing. All these advancements can be largely contributed to President Obama’s 
funding policies.  
Participant 21 (MIP) related the relaxation of funding policies during the Obama 
administration has benefitted scientists due to “access to a greater array of hESC lines 
and through a greater normalization of the field, reducing some of the complications 
associated with working with these cells.” Participant 4 (MRP) related that U.S. 
researchers have benefitted from relaxed policies that govern the use of NIH funds to 
work on established hESC lines. For example, Participant 4 reported that “there is ample 
data to show that different lines of stem cells have intrinsic differences in their ability to 
differentiate into different lineages” and when researchers have the ability to use multiple 
lines of ESCs in NIH-funded research, they are able “to characterize these differences 
and explore the causes to ultimately help understand fundamental properties of 
differentiation.” Participant 4 further noted that researchers still have a lot to learn about 
stem cell function; thus, research is essential. Participant 12 (MSU) noted that relaxed 




cell researchers. Participants 4, 5, 10, 14, 16, 17, 19, and 20 described the Obama 
administration’s funding policy as beneficial to stem cell researchers. 
Some participants expressed approval of the current funding policy, such as 
Participant 2 (MIG) who believed that the policy was beneficial and made it easier for 
researchers to use federal funds to work with new ESC lines. Participant 2 also discussed 
President Bush’s stem cell restrictions and noted that the restrictions for researchers in 
California were not a problem as the voters in California created the CIRM through 
Proposition 71 in 2004, giving the stem cell agency $3 billion to fund stem cell research 
in the state. Thus, Participant 2 emphasized that while researchers in other states faced 
barriers and strict limits on what they could use their stem cell research funding for, in 
California, researchers did not have such problems as they could bypass the federal 
government and fund their own research. On the other hand, Participant 3 (MSU) related 
that the effects of the more stringent Bush administration policies had a negative effect on 
current research in the United States. In addition, Participant 3 questioned whether 
researchers have benefitted from the more relaxed Obama administration policy as more 
researchers are doing research outside the United States, which he attributed to the Bush 
administration policies. Participant 3 stated, “Once you are banned from doing something 
and you move on to something else, you don’t usually turn back.” Participant 15 (FSU) 
related that scientific research has benefitted from the federal stem cell policy, but noted 
that the policy does not go far enough to have a real effect on medical applications. 




an EO, which can be reversed by any subsequent president; thus, researchers cannot rely 
on the indefinite continuation of the current funding guidelines.  
Participants 1, 6, 7, and 9 reported that while the federal stem cell policy was 
favorable to stem cell research, it had not been implemented. Participant 9 (FSU) stated 
that the relaxed funding policies have not really been implemented and compared stem 
cell research to travelling to Cuba, which she noted “is still incredibly difficult.” 
Similarly, Participant 6 (FIP) related that while there are benefits to the federal stem cell 
policy, the full benefit has not been realized. Participants 1 (FRP) and 7 (MSU) related 
that while the Obama administration’s stem cell policy is a positive step, stem cell 
research is still stagnant and benefits have not increased from 2009 due to a lack of 
bipartisan support.  
Participant 5 (MIG) reported that researchers have benefitted from the relaxed 
restrictions because there are many more hESC lines currently eligible for research 
supported by NIH. However, Participant 5 noted that the use of iPS cells has lessened the 
need for new hESC lines. In addition, Participant 5 related that the stem cells lines that 
were approved for research under the Bush administration appears “to remain the most 
heavily used cell lines because researchers are comfortable with them and have been 
using them for years.” Participant 8 (FIP) reported that President Obama’s EO did not 
make any difference in stem cell research and stated the following: 
For most researchers, the problem with embryonic cells is less ethical than 
scientific. Embryonic cells multiply at an extremely rapid pace and have a 




screening in a lab, but will not be used in people, with the exception of a very 
small number of ophthalmology projects, until their cancer-forming properties can 
be controlled. In the meantime, iPS cells have leapfrogged the need to use them.  
 Subtheme 3: Perceptions of the NIH’s ethical policy. hESC lines have to be in 
compliance with the NIH strict ethical policies (Nature Cell Biology, 2010). Applicant 
institutions proposing research using hESCs derived from embryos donated in the United 
States must use human embryos that were created through IVF for reproductive purposes 
and that were no longer needed for this purpose (NIH, 2015a). In addition, the hESCs 
must be donated by individuals who sought reproductive treatment and gave voluntary 
written consent for the human embryos to be used for research purposes (NIH, 2015a). 
Most participants agreed with the NIH’s ethical policy. Participant 13 (FRU) reported 
that the NIH policy helped to ensure that researchers used stem cell lines responsibly:  
The NIH policy restricted the generation of new stem cell lines. However, there 
needs to be strict supervision on such ethical policies. ESCs have great power and 
ensuring that it is handled responsibly is possible only through strict supervision.  
Similar to Participant 13, Participant 4 (MRP) related that all research, including 
embryonic and stem cell research, should be done ethically by following approved and 
vetted standards. Participant 13 further related that the International Society for Stem Cell 
Research (ISSCR) helped create the first set of standards on ethical embryonic and adult 
stem cell research and recently released an updated set of guidelines. Participant 13 stated 
that all scientific research benefits by following ethical scientific practices and that “there 




of the lines, including protecting patients and donors and helping to maintain the integrity 
of the process.” Participant 21(MIP) described the current ethical policies as “particularly 
strict;” but noted that the NIH ethical guidelines represents “a reasonable compromise 
between the obligation to protect embryo and gamete donors and the desire to help 
advance the science.” Participants 3, 12, and 19 also described the policy as strict while 
sharing that they agreed with it. Participant 3 (MSU) also stated: 
NIH strict policy . . . promoted the idea of nonembryonic use and moved research 
into a different path, which is more universally useful. It also brought up the 
ethical issue of how many embryos would be sacrificed to create one transplant, 
which then created the ethical issue of who could afford to use this process, in 
most cases, meaning only wealthy people could afford to have a chance at using 
the therapy from embryonic tissues. ESCs are not very scalable, so to have 
something of value, the product or service must be scalable.  
Participants 6, 10, 11, 14, 16, 17, 18, and 20 agreed with the policy without any 
reservations. However, Participants 5, 7, 8, and 9 expressed concerns about the NIH 
policy. Participant 9 (FSU) related that while the NIH ethical policy is scientifically 
informed regarding safety and is dynamic as new therapies are always developing, “the 
ethical interpretations of ESC use are not scientifically informed and restrictions should 
be reevaluated without political or religious input.” Participant 8 (FIP) related that ESCs 
used for research purposes have always been harvested from IVF clinics with the express 
permission of the individuals involved. Participant 8 stated that the NIH guidelines do not 




the policy as a potential cause of misunderstanding, stating, “The NIH is legally bound to 
the policies, and as such, has a limiting impact and causes confusion in people’s minds 
about the differences between human embryonic and adult stem cells and their uses for 
research.” Participant 5 (MIG) agreed with the ethics of the policy, but believed that 
certain issues were not addressed. Participant 5 related that informed consent for the 
donors of embryos used to create hESC lines remains an important policy, but he noted 
two concerns. In regard to Participant 5 first concern, he related that “the NIH policy on 
using only embryos left over from IVF may skew the source of new lines to less than 
healthy embryos as these are more likely not to be implanted.” In discussing his second 
concern, Participant 5 related that the Food and Drug Administration (FDA) has not kept 
up with stem cell science in regard to its guidance or requirements for preclinical studies 
needed to move stem cell-based therapies into clinical trials. Participant 5 emphasized 
that he is not arguing that researchers should follow the Japanese model and that he has 
great concerns about the Reliable and Effective Growth for Regenerative Health Options 
that Improve Wellness (REGROW) Act, instead, he noted that he would like to see the 
FDA “issue clear guidance and play a more active role in regulating the unregulated stem 
cell clinics currently marketing unapproved, untested therapies.” Participant 5 also stated,  
Finally, U.S. policy with regard to preventing the FDA from even considering 
applications involving genetic engineering or modification of human embryos 
should not be enshrined perpetually in law as the Dickey-Wicker amendment has 




means that therapies can take up to 20 years and billions of dollars to get 
approval. Very few companies can afford that time or money.  
 Subtheme 4: Perceptions of the Dickey-Wicker Amendment. The Dickey-Wicker 
Amendment restricts the use of federal funds for creating, destroying, or knowingly 
injuring human embryos. Participants’ perceptions of the amendment were divided, with 
Participants 2, 4, 5, 7, 9, 13, and 21 disagreeing with the amendment, while Participants 
1, 6, 10, 11, 12, 14, 16, 18, and 20 expressed their agreement with the amendment. 
Participants 5, 7, and 9 noted that the amendment was irrational. Participant 9 (FSU) 
stated, “I strongly disagree [with the amendment]. This is a religious agenda. Females can 
discard embryos in late menstruation, yet this is not regulated. We don’t scoop them up, 
protect them, [and] have funerals.” Participant 7 (MSU) related that the amendment 
created a path that is based on people’s feelings than on science. Participant 5 (MIG) 
related that the amendment is a clear case of the nonseparation of church and state, which 
puts the beliefs of one religion over that of others and instills those beliefs in federal 
legislation. Participant 5 (MIG) also noted that recent technology had limited the effects 
of the amendment due to the use of iPS cell technology and the continued addition to the 
NIH registry of new hESC lines created with other funds. 
 Participant 21 (FSU) also described the amendment’s restrictions as limited, but 
still significant. Participant 21 (FSU) related that state and private funding have helped 
researchers to work around the restrictions, but the restrictions are still a challenge for the 
field. Participant 13 (FRU) expressed a similar opinion about the limited scope of the 




While it does not restrict the use of hESCs for research purposes, it still restricts 
the generation and establishment of new stem cell lines from embryos. While 
there needs to be strict supervision regarding use and destruction of embryos, with 
the current amendment, the field is restricted to the use of just handful of lines.  
Participants 4 and 8 pointed out that IVF embryos that are not used in stem cell 
research are usually discarded. Participant 4 related that although the amendment was 
designed to protect embryos, it does not do so because although embryos cannot be used 
for federally funded research, they are likely discarded when they are no longer needed 
for fertility treatments. Similarly, Participant 8 related that individuals have three options 
for embryos that are theirs, which are being cryopreserved at an IVF clinic: throw them 
away, donate them to research, or continue to cover the costs of storing them indefinitely. 
Participant 8 reported that most embryos are discarded.  
Participant 3 (MSU) discussed the difficulty of evaluating the amendment and 
noted that he did not have an answer about how the amendment restricts the use of 
federal funds for creating, destroying, or knowingly injuring human embryos. Participant 
3 stated: 
This is a complex issue that deals with ethical issues like the use of eggs [in an] in 
vitro sterilization clinic . . . . Should they be implanted in another female or used 
to further research study? So, with something so complex, it may be best to not 
complicate the issue by using those embryos with federal funds, without a clear 
purpose in mind. The cells of embryos can become abused if people believe there 




I do not have an answer for this question and believe it needs to be discussed 
more at a broader level. 
Similarly, Participants 1 and 17 related that the amendment should remain in 
place until there is a clear understanding of how hESC can be beneficial and the 
amendment should be reviewed annually for changes to funding. Participant 6 (FIP) 
reported that the amendment is needed, but it is limiting in relation to federal funds. 
Participant 2 (MIG) shared that while the amendment prohibits the use of federal funds 
for research on human embryos, it does not limit the use of federal funds for research on 
embryonic cell lines; thus, it has a limited effect on stem cell research. However, 
Participant 2 noted that this could change with a different administration.  
 Subtheme 5: Perceptions of competition between the United States and other 
countries. Participants discussed their perceptions of the extent to which U.S. federal 
policy had slowed U.S. stem cell research relative to the research being conducted in 
other countries. Participants 2, 5, 6, 10, 11, 12, 14, 16, 18, 19, and 21 did not believe that 
the United States lagged behind other countries in relation to stem cell research. 
Participants 10 and 18 shared that the policy has neither diminished nor improved stem 
cell research competitiveness with other countries. Participant 21 (MIP) shared that 
scientists and institutions worked around the Bush administration’s funding restrictions 
with state and private funding and that the United States is among the top tier of countries 
producing key stem cell research advances. Participant 5 (MIG) also described U.S. 




The United States remains in the forefront, but other countries, the UK in 
particular, have in some ways more opportunities to conduct research that it is not 
possible to conduct here. My impression is that at least parts of the European 
Union also allow more. Fortunately, the sheer size of the biomedical research 
enterprise and the amount of funds the United States contributes to research allow 
the United States to remain competitive in all but a few areas. 
Participants 2 (MIG) and 21 discussed the restrictive funding policy of the Bush 
administration. Participant 2 shared that the restrictions during the Bush administration 
resulted in U.S. researchers being at a disadvantage compared to researchers in Europe 
and Asia. However, Participant 2 noted that the United States no longer lags behind other 
countries and in many ways is as or more advanced than most countries. Some 
participants shared that the Obama administration’s relaxation of funding restrictions had 
improved United States’ competitiveness. Participant 20 (MSU) related that under the 
Bush administration, the stem cell policy was too restrictive, but the “current policy is a 
good balance of ethics and ability to do research.” Participant 12 (MSU) shared that 
United States’ competitiveness has improved, the country does not lag behind in stem cell 
research, and an example of this is that his group has had a large growth. Similarly, 
Participant 19 (FRP) agreed that the situation for U.S. researchers had been improved due 
to the Obama administration’s policies, which have helped the United States to become 
more competitive with other countries. Similar to Participants 12 and 19, Participant 7 
shared that the Obama administration’s more expansive policy has improved 




lack of using federal funds.” Participant 12 also argued that if the stem cell policy is 
further relaxed, U.S. research could have a global effect.  
 Some participants noted that the federal policy has hindered U.S. stem cell 
research. Participant 1 (FRP) reported that stem cell research has not improved and more 
research should be done. Similarly, Participant 13 (FRU) related that U.S. stem cell 
policy has diminished United States’ competitiveness with other countries; specifically, 
Japan and Europe. Participant 13 also noted that for the last 5 years there has been an 
increase in U.S. studies; however, while such studies are at the forefront, the volume of 
research and the number of stem cell researchers in the United States are still limited. 
Participant 15 (FSU) indicated that restrictions on stem cell research in the U.S. might 
give an advantage to other countries, such as China, since the chances for a breakthrough 
and discovery are greatly increased in places other than the United States. Participant 15 
also recommended that researchers and the stem cell community advocate for more 
relaxed stem cell policies as some hESC lines are still needed for research since iPS cells 
may not behave exactly the same as embryonic cells. Therefore, Participant 15 noted that 
researchers need to continue their examination of all stem cell types since they do not 
know which one will be the best to use in therapy. Participant 6 (FIP) shared that due to 
limitations in the United States, companies who want to be more competitive do research 
in other countries and then bring the results of their research to the United States, which 
makes it very costly for everyone to reap the benefits. Participants 8 (FIP) and 9 (FSU) 
agreed that federal restrictions were causing the United States to lag in stem cell research. 




to stringent FDA regulatory requirements, which are stricter than those of other countries. 
Participant 4 (MRP) related that the federal policy has slowed the creation of new lines of 
hESCs, since that research can only be done using nonfederal funds. Participant 4 also 
stated, “While funding science to the highest levels makes economic sense for our 
country, stem cell research is a global enterprise, and discoveries and stem cell-derived 
therapies in one country will benefit those in other countries.” 
Research Question 2 
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the moral disagreement with stem cell research? Based on Research Question 2 
analyzed data, one overarching theme and five subthemes emerged to answer this 
research question. Participants expressed a variety of perceptions of the moral debate 
surrounding hESC research. Some participants believed that opposition to the research 
was invalidated either by its subjective or irrational impetus or by its failure to address all 
the facts. Participants also noted that the scope of the disagreement was limited to hESCs 
and that emerging iPS cell technology might render it moot. Regarding the possibility of 
compromise between proponents and opponents of hESC research, two participants were 
pessimistic, while other participants viewed iPS cell research as an existing compromise. 
Some participants believed that education about hESC research would lead to widespread 
acceptance of the technology.  
In regard to the context of each research setting, the majority of the participants 
agreed that until religion has been removed from the stem cell debate, a compromise is 




outcome of stem cell research, participants discussed the need for a bipartisan bill, greater 
education, and a stable policy that does not change every 4 to 8 years. Table 5 depicts the 
occurrences and percentages for perceptions of the moral disagreement subthemes. 
Theme 2: Perceptions of the moral disagreement about stem cell research. 
This theme has five subthemes, which are as follows: (a) understanding opposition, (b) 
religious or moral objections, (c) stem cell source, (d) reasoning, and (e) the possibility of 
compromise. Participants’ responses are categorized in the five subthemes below.  
Table 5 
Subtheme Occurrences and Percentages for Perceptions of Moral Disagreement 
Theme Subthemes No. of occurrences % of occurrences 
Perceptions of the 
moral disagreement 
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Subtheme 1: Understanding opposition. Participants 10, 11, 12, 16, and 18 noted 
that they understood, but did not agree with the ethical objections to hESC research. 
Participants 10 (FIP) and 12 (MSU) related that they understood the perceptions and 




for research purposes. Participants 11 (FSU) and 16 (FRP) acknowledged the 
disagreement, but emphasized the necessity for an ongoing dialogue. Participant 11 
shared that the disagreement is understandable, but the topic should be further discussed. 
Participant 16 stated, “I am sympathetic to it, but at the same time, the beneficial aspects 
of this research can be insurmountable, so there needs to be ongoing communication.” On 
the other hand, Participant 18 (FRP) noted that everyone has a right to their own belief.  
Subtheme 2: Religious or moral objections. Some participants were less 
sympathetic toward opponents of hESC research. Participant 1 (FRP) abstained from 
making a judgment and shared that “a lot of the moral disagreement is related to the 
Christian views related to how embryos are being used to accomplish scientist goals.” 
Participant 15 FSU) believed that opposition to hESC research was due to combination of 
political calculation and misdirected sentiment: 
I do not believe there is a moral disagreement; rather a religious perception and 
power calculations to distract the electorate from important social and political 
issues. Morality is intimately linked to politics in the United States. We have the 
moral obligation to save lives. If the material we use was procured from 
spontaneous abortions or medically recommended abortions, we are not 
conducting an immoral activity. 
Participant 2 (MIG) was sympathetic to stem cell opponents’ belief about stem 
cell research and related that there are many people with strong religious faith who are 
opposed to the use of fetal tissue or ESCs in research because they consider these a 




use of fetal tissue or ESCs is ethically or morally wrong. Participant 2 noted an 
“obligation to pursue the use of these materials in scientific work because of their 
enormous potential to save the lives of millions of people around the world who are 
currently battling deadly diseases and disorders that have no cures.” Participant 5 (MIG) 
reported that the moral disagreement with stem cell research is rooted primarily in 
Christianity and discussed the lack of separation of church and state. Participant 5 also 
noted that while the adult stem cells have many advantages, they also have limitations 
when compared to hESCs.  
Participant 14 (FIG) also discussed the connection between religious opposition to 
hESC research as well as religious opposition to abortion. Participant 14 noted that many 
opponents of stem cell research, like religious leaders, compared stem cell research to 
abortion. Participant 14 noted that for the Catholic Church, life begins at conception, 
which makes stem cell research comparable to homicide because it results in the 
destruction of many embryos. Participant 14 noted that from a moral standpoint, stem cell 
research may be perceived as wrong, but researchers are right in doing stem cell research. 
Participant 4 (MRP) also discussed the connection between the opposition to abortion and 
hESC research. Participant 4 noted that the misperception that hESC research is 
connected to abortion will continuously entangle this research in political debates. 
Participant 4 argued that embryos no longer needed for fertility treatments will be 
discarded as medical waste if they are not donated to science or adopted by another 
couple, which rarely occurs. Thus, stopping ESC research does not save the embryos. 




with stem cell research in relation to abortion. Participant 20 (MSU) shared that the moral 
disagreement about hESC research was between an ethical consensus among medical 
professionals and the subjective reactions of some private individuals. Participant 20 
shared that the moral issue is a personal issue because the U.S. policy is in line with most 
bioethics considerations.  
 Subtheme 3: Stem cell source. Three participants out of 21 (14%) noted that the 
moral disagreement surrounding stem cell research depended on the source of the cells in 
question. Participant 1 (FRP) stated, “In the United States, we get caught up with the 
logistics, such as whether the stem cells are being used from human embryos or from 
one’s own stem cells, which is two different processes, but is still misunderstood to this 
day.” Participant 4 (MRP) related that the disagreement with stem cell research is over 
the destruction of embryos to create hESC lines and not over stem cell research in 
general. Participant 21 (MIP) related that the debate over the moral status of the embryo 
will remain stagnant and will continue to shape public opinion toward the field. On the 
other hand, Participant 4 was more optimistic about the chances for a satisfactory 
resolution due to emerging technology. Participant 4 stated, “More companies are 
moving to fibroblast stem cell [iPSC] research, so the issue will become invalid soon, 
essentially making it a nonissue.”  
 Subtheme 4: Reasoning. Some participants questioned the validity of the debate, 
not because the reason for disagreement was religious or moral, but because they 
perceived the reasoning of hESC research opponents as flawed. Participant 7 (MSU) 




people understood that most of the vaccines that “have been derived from these tissues 
being discussed and if they looked further into what the actual usage is and reasons are 
behind it, most people would understand the importance of the research.” Similarly, 
Participant 17 (FRP) related that the moral disagreements with stem cell research are 
mainly due to lack of scientific knowledge and factual information because many times 
facts are misrepresented, which perpetuates a false perception. Participant 17 believed 
that hESC research might be promoted by an appeal to common sense and argued that 
instead of wasting stem cells, why not put them to good use that benefits all people. 
Participant 8 (FIP) believed that public’s understanding of the controversy was impaired 
by equivocal terminology: 
There is no moral disagreement about stem cell research. You shed your skin 
regularly because skin stem cells are constantly renewing and replacing damaged, 
old skin. You can donate a lobe of your liver and it will grow back because liver 
stem cells will regenerate it. Every tissue in your body constantly renews itself 
through tissue-specific stem cells. To say you have a moral disagreement with 
stem cell research is like saying you object to your liver. There is controversy 
about the use of ESCs for research, but I see it as a far greater issue in the lay 
public than it is in the research community. Most scientists I know find it less an 
ethical problem than a scientific one. Because ESCs form cancers, their primary 
contribution will continue to be disease modeling and drug screening. And the 




by the discovery of iPS cells. Even the Vatican supports and funds adult and iPS 
cell research. 
Subtheme 5: The possibility of compromise. Participants 4 and 5 believed that 
compromise between proponents and opponents of stem cell research was unlikely. 
Participant 4 related that compromise is not possible, while Participant 21 (MIP) shared 
that compromise is not likely for those with strong views on the moral status of the 
human embryo. Participant 5 suggested that the benefits of hESC research might 
gradually persuade its opponents:  
Unfortunately, I do not think hESC opponents are willing to compromise, but 
when hESC-based treatments [and] therapies for diseases that afflict them or their 
family members become available, I hope they will take advantage of them and 
maybe reconsider their stance. 
Participants 3, 10, 15, 16, and 21 believed that deriving the necessary research 
materials from uncontroversial sources would render the hESC debate moot. Participant 
21 suggested that focus on less contentious technologies, such as iPS cells and use of 
existing rather than new hESC lines offer some hope. Similarly, Participants 10 (FIP) and 
16 (FRP) noted that continued use of iPS cells can be considered as a compromising 
option. Participant 15 (FSU) noted that the use of iPS cells is a compromise with stem 
cell research opponents; however, researchers still do not know the real potential of this 
technology and its application to therapy. Participant 3 (MSU) suggested that contention 
could be alleviated by working to develop and improve lines in which ethical issues have 




 Some participants recommended more effective education of the public as a 
means of promoting compromise. Participant 7 (MSU) placed the burden of promoting 
education on opponents of stem cell research. Participant 7 shared that compromise can 
occur with the use of more meaningful questions about stem cell research outcomes, 
“such as what does the research mean to my family and to the country now and into the 
future.” Participant 6 (FIP) placed the burden on proponents of stem cell research, 
suggesting that they should “provide a greater understanding.” Participant 12 (MSU) 
referred to education and the concurrent use of uncontroversial materials as a means of 
achieving a compromise: 
I believe the best compromise is using other stem cell lines beyond embryonic 
and making the public aware of the differences. For example, hMSCs [human 
mesenchymal stem cells], which we use, are from a human, adult, healthy donor 
and these cells have shown to be great in curing very devastating conditions such 
as stroke or cardiac problems.  
Research Question 3 
What do U.S. stem cell researchers, stakeholders, and investors recommend to 
improve stem cell research policy in the United States? Based on Research Question 3 
analyzed data, one theme and four subthemes emerged to answer this research question. 
Participants suggested that U.S. federal stem cell policy could be improved by (a) 
excluding religious considerations from political discussions, (b) involving outsiders and 




and disadvantages of stem cell research for laypersons and legislators, and (d) increasing 
federal funding.  
In regard to the context of each research setting, researchers, investors, and 
stakeholders recommended the need for increased federal funding to improve stem cell 
research in the United States as well as the need to educate the general public and 
lawmakers. Stakeholders recommended including people from the outside in stem cell 
discussions and removing religious agendas. Table 6 depicts the occurrences and 
percentages for policy recommendations subthemes. 
Theme 3: Policy recommendations. This theme has four subthemes, which are 
as follows: (a) funding, (b) involving outsiders, (c) excluding religion, and (d) education. 
Participants’ responses are categorized in the four subthemes below.  
Table 6  
Subtheme Occurrences and Percentages for Policy Recommendations 































 Subtheme 1: Funding. Participants 1, 2, 8, 9, 20, and 21 made policy 
recommendations to increase federal funding. Participant 2 (MIG) shared that it is going 




Participant 8 (FIP) summarized her recommendations in the form of an equation, stating, 
“Streamlined process plus money equals competitive advantage, where streamlined 
process referred to an acceleration of the FDA approval process. Participant 2 also 
mentioned FDA requirements and noted that it is “going to take changes in the way the 
FDA regulates stem cell therapies to enable the science to move ahead as fast as it needs 
to.” Participants 1, 9, 20, and 21 also recommended an increase in federal funding. 
 Subtheme 2: Involving outsiders. Participants 3 and 7 suggested involving 
outsiders and laypersons in the stem cell research discussion. Participant 3 (MSU) 
recommended bringing in people from the outside, not just professionals. Similarly, 
Participant 7 (MSU) also recommended the engagement of lay people who are recipients 
of the therapy along with professionals in the field. Participant 7 explained that involving 
the public might be an effective political agenda because “people are very similar when it 
comes to saving lives. People respect human life and are more practical in their 
understanding if they can relate outcomes to their own family and loved ones.” 
Subtheme 3: Religion. Participant 9 (FSU) recommended the removal of 
religious agendas from the dialogue, stating, “The ethical interpretations to ESC use are 
not scientifically informed and restrictions should be reevaluated without political or 
religious input.” In addition, Participant 9 recommended that legislators vote to overturn 
religious agendas because stem cell research will not move forward until the policies 
change. 
Subtheme 4: Education. Some participants recommended different forms of 




recommended “improved science education, public announcements educating the public, 
[and] encouraging open discussion of policy, ethics, and science.” Participant 14 (FIG) 
shared that the general public should be educated about the benefits of stem cell research 
because they do not know enough. Participant 14 recommended reaching out to 
community residents. Participant 17 (FRP) recommended educational outreach where 
both sides of stem cell research are discussed with stakeholders with the goal of reaching 
a common, middle ground. Participant 19 (FRP) agreed with Participant 17 and 
recommended that people need to be educated on the advantages and disadvantages of 
stem cell research. Participant 1 (FRP) suggested that educational efforts should not only 
focus on the general public, but that lawmakers should be educated as well. 
Summary of Findings 
The purpose of this qualitative phenomenological research study was to explore 
the perceptions of 21 stem cell researchers, stakeholders, and investors in the United 
States about the effects of the current federal stem cell policy on stem cell research in the 
United States, the moral disagreement with stem cell research, and recommendations to 
improve stem cell research policy in the United States. In-depth telephonic 
semistructured interviews with 21 stem cell researchers, stakeholders, and investors in the 
United States were used to address the three research questions. Using Attride-Stirling’s 
(2001) six steps or stages on how to conduct a thematic analysis, three overarching 
themes (perceptions of the effects of the Obama administration’s federal stem cell policy, 




and 14 subthemes emerged in answering the research questions. The 14 subthemes are 
discussed below.  
First, in regard to U.S. stem cell researchers’, stakeholders’, and investors’ 
perceptions about the effects of the current federal stem cell policy on stem cell research 
in the United States, participants discussed their perceptions of the Obama 
administration’s funding policy, the NIH’s ethical policy, the Dickey-Wicker 
Amendment, and competition between the United States and other countries. Findings 
indicated those participants’ perceptions of U.S. federal stem cell policy varied widely as 
some participants perceived the policy as beneficial, irrelevant, or a constraint on stem 
cell research. Only a few participants expressed approval of the current stem cell policy. 
Some participants who perceived the federal stem cell policy as beneficial to U.S. stem 
cell research expressed their approval, stating that the Obama administration’s 
comparatively relaxed funding policy was more advantageous to stem cell researchers 
than the Bush administration’s restrictions, although the Obama administration’s policy 
was not necessarily optimal. Some participant noted that while the federal stem cell 
policy makes it easier to do more research, funding is still slow due to past policies and 
restrictions. Some participants described the policy as a significant constraint because 
despite all the testing that is taking place, the benefit from stem cell is still not fully 
realized. Other participants believed that funding restrictions, which only affected 
research conducted on hESCs, had lost much of their significance with the increasing 
prevalence of research involving iPS cells and adult stem cells. Six participants (29%) 




were invalidated by their reliance on justifications that were perceived as irrational, 
although 13 participants (62%) agreed with the amendment. Almost all participants, 
however, agreed with the NIH ethical policy, with 17 of 21 participants (81%) describing 
the policy as a valuable means of promoting ethical science. Some participants expressed 
concerns about the NIH policy, such as the ethical interpretations of ESC use are not 
scientifically informed and restrictions should be reevaluated without political or 
religious input. Some participants highlighted that restrictive stem cell policies could 
have a negative effect on the international standing of U.S. stem cell research because 
major research companies move their stem cell research division to other countries where 
scientists are permitted to conduct research without any restriction. 
Second, in regard to U.S. stem cell researchers’, stakeholders’, and investors’ 
perceptions about the moral disagreement with stem cell research, participants discussed 
understanding of the opposition, religious or moral objections, stem cell source, 
reasoning, and the possibility of compromise. Findings indicated that participants had 
different perceptions of the moral debate surrounding hESC research. Some participants 
believed that opposition to the research was invalidated either by its subjective or 
irrational impetus or by its failure to address all the facts. Some participants shared that 
opposition to hESC research was due to combination of political calculation and 
misdirected sentiment. Some participants also discussed the connection between religious 
opposition to hESC research as well as religious opposition to abortion. Some 
participants noted that embryos no longer needed for fertility treatments were discarded 




stopping ESC research does not save the embryos. Participants also noted that the scope 
of the disagreement was limited to hESCs and that emerging iPS cell technology might 
render it moot. Hence, some participants pointed out that the disagreement with stem cell 
research is over the destruction of embryos to create hESC lines and not over stem cell 
research in general. Some participants questioned the validity of the stem cell debate 
because they perceived the reasoning of hESC research opponents as flawed. Regarding 
the possibility of compromise between proponents and opponents of hESC research, 
some participants were pessimistic, while other participants viewed iPS cell research as 
an existing compromise. Some participants believed that education about hESC research 
would lead to widespread acceptance of the technology. 
Third, in regard to what U.S. stem cell researchers, stakeholders, and investors 
recommend to improve stem cell research policy in the United States, participants 
discussed funding, involving outsiders, excluding religion, and the need for education. 
Findings indicated that participants believed that the U.S. federal stem cell policy could 
be improved by excluding religious considerations from political discussions, involving 
outsiders and nonprofessionals in the debate, promoting outreach education about the 
advantages and disadvantages of stem cell research for laypersons and legislators, and 
increasing federal funding. In Chapter 4, I included the introduction, setting, 
demographics, data collection, data analysis, evidence of trustworthiness, results, and a 
summary. In Chapter 5, I include the introduction, interpretation of findings, limitations 




Chapter 5: Discussion, Conclusions, and Recommendations 
In this phenomenological study, I explored seven U.S. stem cell researchers’, 
seven U.S. stakeholders’, and seven U.S. investors’ perceptions about the effects of the 
current federal stem cell policy on stem cell research in the United States, the moral 
disagreement with stem cell research, and recommendations to improve stem cell 
research policy in the United States. I collected data through in-depth telephonic 
semistructured interviews. This study was designed to answer three research questions: 
(a) U.S. stem cell researchers’, stakeholders’, and investors’ perceptions about the effects 
of the current federal stem cell policy on stem cell research in the United States, (b) U.S. 
stem cell researchers’, stakeholders’, and investors’ perceptions about the moral 
disagreement with stem cell research, and (c) U.S. stem cell researchers, stakeholders, 
and investors recommendations to improve stem cell research policy in the United States. 
Using Attride-Stirling’s (2001) six steps of thematic analysis, I found three 
overarching themes (perceptions of the effects of the Obama administration’s federal 
stem cell policy, perception of moral disagreement about stem cell research, and policy 
recommendations) and 14 subthemes. Findings indicated that participants’ perceptions of 
U.S. federal stem cell policy varied as some participants perceived the policy as 
beneficial while others perceived it as irrelevant or a constraint on stem cell research. 
Only a few participants expressed approval of the current stem cell policy. Some 
participants who perceived the federal stem cell policy as beneficial noted that the Obama 




cell researchers than the Bush administration’s restrictions, although the Obama 
administration’s policy was not necessarily optimal.  
In sharing their perceptions about the moral disagreement with stem cell research, 
participants discussed understanding of the opposition, religious or moral objections, 
stem cell source, reasoning, and the possibility of compromise. Findings indicated that 
participants had different perceptions of the moral debate surrounding hESC research 
where some participants believed that opposition to the research was invalidated either by 
its subjective or irrational impetus or by its failure to address all of the facts. Participants 
also noted that the scope of the disagreement was limited to hESCs and that emerging iPS 
cell technology might render it moot. Some participants pointed out that the disagreement 
with stem cell research is over the destruction of embryos to create hESC lines and not 
over stem cell research in general. Findings also indicated that participants believed that 
the U.S. federal stem cell policy could be improved by excluding religious considerations 
from political discussions, involving outsiders and nonprofessionals in the debate, 
promoting outreach education about the advantages and disadvantages of stem cell 
research for laypersons and legislators, and increasing federal funding. In Chapter 5, I 
present the interpretation of findings, limitations of the study, recommendations, 
implications, and a conclusion. 
Interpretation of the Findings 
I explored seven stem cell researchers’, seven stakeholders’, and seven investors’ 
perceptions in the United States about the effects of the current federal stem cell policy 




research, and recommendations to improve stem cell research policy in the United States. 
This qualitative phenomenological study was designed to answer three research 
questions. The findings are interpreted in the context of Rogers’s (1962) DOI theory, 
Kingdon’s (1995) agenda-setting theory, and the literature review. This section contains 
the following subsections: Research Question 1, Research Question 2, and Research 
Question 3.  
Research Question 1 
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the effects of the current federal stem cell policy on stem cell research in the United 
States? The results of Research Question 1 included participants’ perceptions of the 
Obama administration’s funding policy, the NIH’s ethical policy, the Dickey-Wicker 
Amendment, and competition between the United States and other countries. 
Participants’ perceptions of U.S. federal stem cell policy varied widely as some 
participants perceived the policy as beneficial while others perceived it as irrelevant or a 
constraint on stem cell research. Only a few participants expressed approval of the 
current stem cell policy. Some participants who perceived the federal stem cell policy as 
beneficial stated that the Obama administration’s comparatively relaxed funding policy 
was more advantageous to stem cell researchers than the Bush administration’s 
restrictions, although the Obama administration’s policy was not necessarily optimal. 
Some participants noted that although the current stem cell policy makes it easier to do 
more research, funding is still slow due to previous policies and restrictions. Some 




that is taking place, the benefits from stem cell research are not fully realized. Other 
participants reported that funding restrictions, which only affected research conducted on 
hESCs, had lost much of their significance with the increasing prevalence of research 
involving iPS cells and adult stem cells. Six participants (29%) commented that current 
funding restrictions prescribed by the Dickey-Wicker Amendment were invalidated by 
their reliance on justifications that were perceived as irrational, although 13 participants 
(62%) agreed with the amendment. Almost all participants agreed with the NIH ethical 
policy, with 17 participants (81%) describing the policy as a valuable means of 
promoting ethical science. Some participants expressed concerns that ethical 
interpretations of ESC use are not scientifically informed and restrictions should be 
reevaluated without political or religious input. Some participants highlighted that 
restrictive stem cell policies could have a negative effect on the international standing of 
U.S. stem cell research because major research companies move their stem cell research 
division to other countries where scientists are permitted to conduct research without any 
restriction. 
Findings from Research Question 1 may be interpreted using Rogers’s (1962) 
DOI theory. Restrictive stem cell policies could have a negative effect on the 
international standing of U.S. stem cell research as major research companies move their 
stem cell research division to other countries where scientists are permitted to conduct 
research without restriction. Amidon (2005) noted that limiting the spread of innovation 
slows growth. Rogers (1995) argued that diffusion, which is the means of how 




of a new product, idea, or practice from being accepted by others of a particular culture or 
network. The DOI theory can also be applied to the finding that although the current stem 
cell policy makes it easier to do research, funding is still slow due to previous policies 
and restrictions. This finding is consistent with what has been reported in the literature 
where differences in national regulatory approaches have generated competition to 
implement stem cell programs that will give countries an edge in the global knowledge 
economy (Gottweis et al., 2009). Countries such as China, India, South Korea, and 
Singapore have been identified as emerging biotech powers (Wahlberg, 2012). 
Some participants described the U.S. stem cell policy as a significant constraint 
because despite all the testing that is taking place, the benefits from stem cell are not fully 
realized. This finding can be examined using Rogers’s (1995) discussion of the diffusion 
and adoption step in the innovation-development process. Rogers noted that this is the 
most difficult step in the innovation-development process, which involves diffusing the 
product to potential adopters. As with all new products, there is pressure to move it to 
market due to the problem and need being high priority. Sometimes public funds are used 
until there is a positive outcome that will be beneficial to potential adopters. The move to 
market is where scientists seem to have the greatest concern around innovation, which 
includes unveiling the product and putting it into practice. 
Participants’ perceptions that the Dickey-Wicker Amendment was irrational and 
that restrictions from the amendment are a challenge for the stem cell field are consistent 
with the Kingdon’s (1995) agenda-setting theory. In regard to Kingdon’s three streams 




hESC began with the 1998 discovery that introduced new possibilities, and scientists 
sought to gain more funding through government sponsorship. According to 
Chayabunjonglerd, scientists argued that the Dickey-Wicker Amendment that banned the 
use of human embryos in federally funded projects hindered significant advances in 
health care. Chayabunjonglerd noted that the issue of federal funding of hESC research 
raised the important question of whether the government should fund hESC research. 
Chayabunjonglerd claimed that President Bush’s inauguration represented significant 
change in the political stream, which opened a window for him to push forward his policy 
on hESC research. This resulted in the policy stream, where President Bush issued a 
Presidential Statement in 2001 that limited federal funding of research involving hESCs 
(Chayabunjonglerd, 2012; Obama, 2009). 
Some participants commented that the federal stem cell policy was beneficial to 
U.S. stem cell research and expressed their approval, stating that the Obama 
administration’s comparatively relaxed funding policy was more advantageous to stem 
cell researchers than the Bush administration’s restrictions, although the Obama 
administration’s policy was not necessarily optimal. This finding is consistent with what 
has been reported in the literature. Hyun (2010) related that although the controversy over 
embryo destruction continues, the Obama administration’s friendlier stance toward hESC 
research has helped the proponents’ public debate over hESC research. President 
Obama’s EO removed limitations on scientific inquiry and expanded the NIH support for 
the exploration of stem cell research, with the purpose of enhancing the contributions of 




humanity (Obama, 2009). However, despite President Obama’s reversal of some of the 
barriers to hESC research, questions remain about the extent to which U.S. stem cell 
researchers have truly benefited from this more relaxed federal funding policy (Nature 
Cell Biology, 2010; Wolinsky, 2009).  
Research Question 2 
What are U.S. stem cell researchers’, stakeholders’, and investors’ perceptions 
about the moral disagreement with stem cell research? The results of Research Question 
2 included participants’ understanding of the opposition, religious or moral objections, 
stem cell source, reasoning, and the possibility of compromise. Participants had different 
perceptions of the moral debate surrounding hESC research. Some participants 
commented that opposition to the research was invalidated either by its subjective or 
irrational impetus or by its failure to address all of the facts. Some participants shared that 
opposition to hESC research was due to a combination of political calculation and 
misdirected sentiment. Some participants also discussed the connection between religious 
opposition to hESC research as well as religious opposition to abortion. Some 
participants noted that embryos no longer needed for fertility treatments are discarded as 
medical waste if they are not donated to science or adopted by another couple, and 
stopping ESC research does not save the embryos. Participants also noted that the scope 
of the disagreement was limited to hESCs and that emerging iPS cell technology might 
render it moot. Some participants pointed out that the disagreement with stem cell 
research is over the destruction of embryos to create hESC lines and not over stem cell 




because they perceived the reasoning of hESC research opponents as flawed. Regarding 
the possibility of compromise between proponents and opponents of hESC research, 
some participants were pessimistic while others viewed iPS cell research as an existing 
compromise. Some participants believed that education about hESC research would lead 
to widespread acceptance of the technology. 
Findings from Research Question 2 may be interpreted using Rogers’s (1962) 
DOI theory. Some participants discussed the connection between religious opposition to 
hESC research and religious opposition to abortion. Rogers (2003) argued that there are 
five factors that influence the adoption of innovation probability rate: (a) relative 
advantage, (b) compatibility, (c) complexity, (d) trialability, and (e) observability. 
Compatibility is determined by the acceptability of social or religious norms in the 
country, which may forbid certain practices, attitudes, or behaviors. Findings from the 
current study indicated that some participants believed that education about hESC 
research would lead to widespread acceptance of the technology. Rogers also discussed 
the five innovation-decision processes: (a) knowledge, (b) persuasion, (c) decision, (d) 
implementation, and (e) confirmation. In the knowledge stage, individuals are exposed to 
an innovation, but they do not have information about the innovation. Perhaps additional 
knowledge about hESC research, such as the knowledge that embryos no longer needed 
for fertility treatments are discarded as medical waste if they are not donated to science or 
adopted by another couple, may lead to more widespread acceptance of hESC research.  
The finding that opposition to hESC research was due to a combination of 




agenda-setting theory. In the politics stream, Kingdon noted that politics are factors that 
influence agendas, such as political climate or mood and the voices of advocacy or 
opposition groups. Findings indicated that participants had different perceptions of the 
moral debate surrounding hESC research. This finding is consistent with the literature 
indicating that the ethical and moral disagreement about hESC research and the 
destruction of embryos continues between proponents of religion and science 
(Doerflinger, 2010). Stem cell research remains highly controversial because there are 
unresolved questions about human cloning, therapeutic abortions, and reproductive rights 
(Adelson & Weinberg, 2010). Lysaght and Campbell (2012) reported that there are 
concerns that have generated political and public bioethical debates. Fadel (2012) 
discussed the issue of ethics in stem cell research and noted that it remains a lengthy and 
heated debate in the scientific literature, religious circles, and the political arena. Fadel 
noted that the debate includes the need to protect human life from the time of inception 
versus curing many debilitating diseases. 
Regarding the possibility of compromise between proponents and opponents of 
hESC research, some participants were pessimistic, while other participants viewed iPS 
cell research as an existing compromise. This finding is consistent with the literature as 
those in support of hESC research have argued that it is morally permissible to use 
surplus embryos for biomedical research that may save many lives (Mintrom, 2013). 
However, those who oppose hESC research do not agree with this argument and have 
argued that such research would still support the destruction of embryos. Levine (2011) 




policymaking in other morally charged areas, policy certainty will continue to prove 
difficult. Hence, some degree of uncertainty may be unavoidable and as a result, hESC 
researchers should prepare for continued policy changes, legal challenges, and other 
challenges to their research. Although the controversy over embryo destruction continues, 
Hyun (2010) related that the creation of human iPS cells, which are genetically 
engineered to act like hESCs, have helped the proponents’ public debate over hESC 
research. The researcher noted that the main bioethical considerations now focuses more 
on how stem cell research should be conducted instead of whether it should be 
conducted. Those who oppose hESC research applauded the iPS cell revolution, which 
they hoped would end ESC research. However, most stem cell researchers believe that 
iPS or other alternative source of stem cells do not take away the need for ongoing hESC 
research. Thus, some participants recommended that researchers and the stem cell 
community advocate for more relaxed stem cell policies as some hESC lines are still 
needed for research since iPS cells may not behave exactly the same as embryonic cells. 
Research Question 3 
What do U.S. stem cell researchers, stakeholders, and investors recommend to 
improve stem cell research policy in the United States? The results of Research Question 
3 indicated that participants discussed funding, involving outsiders, excluding religion, 
and the need for education. Participants believed that the U.S. federal stem cell policy 
could be improved by excluding religious considerations from political discussions, 




about the advantages and disadvantages of stem cell research for laypersons and 
legislators, and increasing federal funding. 
Findings from Research Question 3 may be interpreted using Rogers’s (1962) 
DOI theory, such as some participants recommending the removal of religious agendas 
from the dialogue and that legislators vote to overturn religious agendas because stem 
cell research will not move forward until the policies change. Rogers (1995) noted that 
groupthink tends to limit the spread of innovation. Leaders of a group exert influence 
over the behaviors of individuals and adopters in their networks, such as influencing 
followers’ beliefs (Anderson, 2006; Janis, 1989; Rogers, 1983). Limiting the spread of 
innovation also slows down growth (Amidon, 2005). According to Amidon (2005), 
individuals in political or social settings tend to accept groupthink as a form of solidarity 
and unanimity. 
Rogers’s (1962) DOI theory can also be attributed to participants’ 
recommendation to involve outsiders or laypersons as well as well as using different 
forms of education to make federal policy more favorable to hESC research, such as 
improved science education, public announcements educating the public, and 
encouraging open discussion of policy, ethics, and science. Terin (2012) noted that 
diffusion of innovation is connected to an individual’s perception of a new product or 
service, while invention is new. Therefore, Therin related that with the perception of 
newness, there must be knowledge about the service or product, otherwise that perception 
is not relevant. In addition, any new innovation must be known among the targeted 




knowledge about the product and service has been conveyed, there should be a theoretical 
framework in place to rate the adoption of the new innovation. 
Participants’ recommendation to increase funding can be attributed to Kingdon’s 
(1995) agenda-setting theory. Dresser (2010) reported that in the United States, the stem 
cell controversy opens a window to a larger moral problem (Dresser, 2010). According to 
Dresser (2010), the social justice inquiry about what justifies the United States substantial 
investment in biomedical innovation, when millions of people in the United States and 
abroad are denied access to proven medical interventions, raises questions about the 
priority that stem cell and other basic science studies should have in the competition for 
limited resources. Dresser argued that if government officials and health advocates want 
to help patients, meaningful help would also come from a system that supplied adequate 
health care to more people, both across the nation and worldwide.  
Participants’ recommendation for increase funding is also consistent with the 
literature. Adelson and Weinberg (2010) noted that the continuous changes in the policy 
by each President have been a source of great concern for representatives of states such 
as California, who support hESC research. Therefore, states such as California, have 
added additional revenue to the budget to further stem cell research programs. For 
example, in 2004, after President Bush’s policy denied the use of federal funds to further 
research, California officials created the California Research Cures Initiatives to continue 
with their research after law was passed to stop federal funding to support stem cell 
research and to ban those who continued their study on stem cells from using laboratories 




to provide oversight and created funding for all research in their state. The CIRM agreed 
to contribute $3 billion over a decade and create another $3 billion through the sale of 
public bonds and the state general fund to aid in the study of stem cells. Gottweis et al. 
(2009) emphasized that differences in national regulatory approaches have generated 
competition to implement stem cell programs that will give countries an edge in the 
global knowledge economy. 
Limitations of the Study 
There were several limitations of this study. First, findings were limited by the 
snowball sample of seven stem cell researchers, seven stem cell stakeholders, and seven 
stem cell investors; each category of participants contained a smaller number than the 
overall sample of 21. Due to the small sample size for each category of participant, 
caution has to be taken in transferring the findings to similar populations of U.S. stem 
cell researchers, stakeholders, and investors. In addition, the results of the study may not 
be transferrable to other populations or countries. As a result, in future research, the 
sample population for each type of participant could be increased to achieve a broader 
understanding of their stem cell research policy experiences. In future studies, a different 
sampling strategy could also be used, such as random sampling. 
Second, social desirability bias was considered as stem cell researchers, 
stakeholders, and investors may have wanted to be perceived positively, so they may not 
have responded honestly to the interview questions. However, I assumed that participants 
would honestly and openly answer the interview questions by sharing their perceptions 




participants may not have accurately or fully evaluated themselves. However, I assumed 
that participants accurately and fully self-evaluated.  
Recommendations 
 The six recommendations for future studies are grounded in the strengths and 
limitations of the study as well as the literature reviewed in Chapter 2: (a) Use random 
sampling for each group of participants, (b) focus on how subsequent U.S. administration 
stem cell policies affect stem cell research in the United States, (c) focus on the general 
public’s knowledge of stem cell research as well as those of legislators, (d) focus on 
involving outsiders and laypersons in the stem cell research discussion, (e) investigate the 
divisiveness of the hESC research debate and what can be done to create a cohesive or 
bipartisan federal ESC public financing policy, and (f) focus on examining and 
comparing international communities’ stem cell policies. These six recommendations are 
discussed in further detail below.  
First, as noted in the limitations of the study section, it is recommended that in 
future research studies, the sample population for each type of participant (stem cell 
researchers, stakeholders, and investors) could be increased to achieve a broader 
understanding of their stem cell research policy experiences. In doing this, different 
sampling strategies could also be used, such as random sampling. Second, policy 
uncertainty affects researchers’ plans more significantly than temporary funding bans 
(Levine, 2011). Adelson and Weinberg (2010) noted that continuous changes in the 
policy by each President have been a source of great concern for representatives of states. 




administration. Kingdon (1995) related that windows can predictably or unpredictably 
appear due to events such as election results or a sudden crisis, respectively (Kingdon, 
1995). Therefore, future research could focus on how subsequent U.S. administration 
stem cell policies affect stem cell research in the United States, such as those of the new 
Trump administration. 
Third, participants suggested that educational efforts should focus on the general 
public as well as lawmakers. Thus, future research studies could focus on the general 
public’s knowledge of stem cell research as well as those of legislators. Fourth, 
participants suggested involving outsiders and laypersons in the stem cell research 
discussion; thus, future research studies could focus on this recommendation. Fifth, some 
participants noted that while the Obama administration’s stem cell policy is a positive 
step, stem cell research is still stagnant and benefits have not increased from 2009 due to 
a lack of bipartisan support. Thus, future research could further investigate the 
divisiveness of the hESC research debate and what can be done to create a cohesive or 
bipartisan federal ESC public financing policy.  
Sixth, participants shared that the Obama administration’s more expansive policy 
has improved competitiveness, but researchers are still restricted to the creation of new 
lines due to the lack of using federal funds. In addition, participants argued that if the 
stem cell policy is further relaxed, U.S. research could have a global effect. Participants 
argued that U.S. stem cell policy has diminished United States’ competitiveness with 
other countries; such as China, Japan, and Europe. Participant also shared that due to 




in other countries and then bring the results of their research to the United States, which 
makes it very costly for everyone to reap the benefits. Thus, future research study could 
focus on examining and comparing international communities’ stem cell policies, such as 
those in China, Japan, Europe, India, South Korea, and Singapore, who have been 
identified as emerging biotech powers (Wahlberg, 2012), with those of the United States 
so that lessons can be learned and to ensure that stem cell research continues to improve 
in the United States. 
Implications 
To improve stem cell research policy in the United States, U.S. stem cell 
researchers, stakeholders, and investors recommended the exclusion of religious 
considerations from political discussions, involving outsiders and nonprofessionals in the 
debate, promoting outreach education about the advantages and disadvantages of stem 
cell research for laypersons and legislators, and increasing federal funding. These 
recommendations have several implications for stem cell policymakers to focus attention 
and resources on creating a consistent federal hESC funding policy to ensure that stem 
cell research continues to improve in the United States. While some participants noted 
that funding restrictions, which only affected research conducted on hESCs, had lost 
much of their significance with the increasing prevalence of research involving iPS cells 
and adult stem cells, other participant recommended that researchers and the stem cell 
community should advocate for more relaxed stem cell policies as some hESC lines are 
still needed for research since iPS cells may not behave exactly the same as embryonic 




health care field as hESCs can be used for cell-based therapies to replace ailing or 
destroyed tissues, such as macular degeneration, spinal cord injury, stroke, burns, heart 
disease, diabetes, osteoarthritis, and rheumatoid arthritis (NIH, 2015b). In addition, 
hESCs can be used to treat Alzheimer’s and Parkinson’s diseases; however, the need for 
transplantable tissues and organs far outweighs the available supply (CIRM, 2015b; NIH, 
2015b).  
Participants recommended the removal of religious agendas from the stem cell 
research policy dialogue. Policy entrepreneurs, who are political actors who seek policy 
changes to existing situations in areas of public policy, have faced significant opposition 
to government funding and favorable regulations to advance hESC research due to 
morality issues (Mintrom, 2013). The most restrictive stem cell laws are in countries 
where Roman Catholicism is a dominant religion or Christian democratic parties have 
been on the rise (Fink, 2008; Mintrom, 2013). Mintrom (2013) reported that the UK has a 
permissive approach to the hESC research regulation and that it is correlated with the low 
percentage of adults who identify with the Roman Catholic faith (9%) in the UK. 
Mintrom noted that in the UK, moral issues have been widely investigated and 
extensively debated; however, they have not inhibited scientific research.  
Unlike the UK and other permissive countries, hESC research in the United States 
is divisive and controversial, which has resulted in continuous stem cell policy 
uncertainty (Levine, 2011; Levine et al., 2013; Mintrom, 2013). Participants related that 
stem cell policies could change with a different administration. Thus, there is no cohesive 




a leading country for the advancement of hESC research (Mintrom, 2013; Sano, 2013). 
As a result, U.S. hESC researchers continue to face policy fluctuations, legal challenges, 
and other hurdles to their future research (Levine, 2011; Levine et al., 2013; Mintrom, 
2013; Sano, 2013).  
Participants recommended that outsiders and nonprofessionals should be involved 
in the stem cell research policy debate and outreach education on the advantages and 
disadvantages of stem cell research should be given to the general public and legislators. 
Participants also related that the moral disagreements with stem cell research are mainly 
due to lack of scientific knowledge and factual information because many times facts are 
misrepresented, which perpetuates a false perception. Thus, with educational outreach, 
where both sides of stem cell research are discussed with stakeholders, a common, 
middle ground may be reached. 
Participants made policy recommendations to increase federal funding as it would 
increase U.S. stem cell research competitive advantage. Gottweis et al. (2009) reported 
that differences in national regulatory approaches have generated competition to 
implement stem cell programs that will give countries an edge in the global knowledge 
economy. Hence, to compete with countries such as China, India, South Korea, and 
Singapore, who have been identified as emerging biotech powers (Wahlberg, 2012), and 
to ensure that everyone can reap the benefits of stem cell research, a cohesive and more 
permissive federal hESC funding policy in the United States is needed. In this study, I 
addressed a gap in research by making an original contribution to the public policy and 




fields of public policy and administration, a wide array of other fields, agencies, and 
organizations might be interested in the research findings as well, to include the fields of 
biology and regenerative medicine, and agencies such as the CIRM and the NIH.  
Conclusion 
To further understand and address the problem of federal support and funding for 
hESC research in the United States being behind stem cell programs in many countries 
and the continually evolving federal policies that have further hindered research efforts, it 
was important to obtain the perceptions of stem cell researchers, stakeholders, and 
investors in the United States about the effects of the current federal stem cell policy on 
stem cell research in the United States, the moral disagreement with stem cell research, 
and recommendations to improve stem cell research policy in the United States because 
they have expertise in the field of stem cell research.. Researchers noted that unlike the 
UK and other permissive countries, hESC research in the United States are divisive and 
controversial, which has resulted in continuous stem cell policy uncertainty (Levine, 
2011; Levine et al., 2013; Mintrom, 2013). There is no consistent federal hESC funding 
policy, which stifles the United States’ standing to be a leading country for the 
advancement of hESC research (Mintrom, 2013; Sano, 2013). Levine (2011) related that 
policy uncertainty affects researchers’ plans more significantly than temporary funding 
bans (Levine 2011). As a result, Levine recommended that lawmakers who are supportive 
of hESC research should work to create policies that reduce the uncertainty facing stem 
cell scientists. Nature Cell Biology (2010) related that while each state government will 




have already done so, a liberal policy at the federal level also softens the tone of hESC 
debate and promote greater acceptance of such research within the United States. As a 
result, from a policy perspective, more remains to be done to ensure that stem cell 
research improves in the United States.  
Findings are directed at stem cell policymakers to focus attention and resources 
on creating a hESC federal funding policy that is cohesive to ensure that stem cell 
research continues to improve the United States. A bipartisan federal hESC funding 
policy will lead to positive social change in the health care field as hESCs can be used for 
cell-based therapies to replace ailing or destroyed tissues, such as macular degeneration, 
spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid 
arthritis (NIH, 2015b). In addition, hESCs can be used to treat Alzheimer’s and 
Parkinson’s diseases; however, the need for transplantable tissues and organs far 
outweighs the available supply (CIRM, 2015b; NIH, 2015b). Therefore, by stem cell 
researchers, stakeholders, and investors educating the general public and lawmakers 
about hESC research, as well as involving the public in stem cell research discussions, 
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Appendix A: Invitation to Participate and Recommendation Request 
 
Dear Name Will Be Inserted Here, 
 
My name is Dorothy Moore and I am currently a doctoral student at Walden University. I 
am exploring the perceptions of stem cell researchers, stakeholders, and investors in the 
United States about the effects of the current federal stem cell policy on stem cell 
research in the United States, the moral disagreement with stem cell research, and their 
recommendations to improve stem cell research policy in the United States. 
 
I would greatly appreciate your participation.  
 
Your participation would involve participating in a telephone interview which would take 
about 45 minutes. Interviews will be conducted at a time that is convenient for you.  
 
The information from the interviews will be kept strictly confidential and no one who 
participates will be identified in any way. 
 
If you have any questions about the study, please feel free to e-mail me at [E-mail 
address redacted] or give me a call at [Phone number redacted]. 
 
If you are interested in participating in the study and/or would like to recommend another 
stem cell researcher who works at a government organization, private company, or 
university; a stem cell stakeholder who is a faculty member at a univeristy where stem 
cell research is being conducted; or an investor who works for a government organization 
or private company that invests in stem cell research in the United States, please 
complete the questions below in a reply e-mail to me.  
 





[Phone number redacted] 
[E-mail address redacted]  
 
If you are interested in participating in the study and/or would like to recommend 
another stem cell researcher, stakeholder, or investor to be a participant in the 






1. Are you a stem cell researcher who works at a government organization, private 
company, or university? (please select by bolding your answer) 
a. Yes 
b. No 
2. Are you a stem cell stakeholder who is a faculty member at a univeristy where 
stem cell research is being conducted? (Please select by bolding your answer) 
a. Yes 
b. No 
3. Are you a stem cell investor who works for a government organization or 
private company that invests in stem cell research in the United States, 
stakeholder, or investor? (Please select by bolding your answer) 
a. Yes 
b. No 
4. What is your gender? (Please select by bolding your answer) 
a. Male 
b. Female 
5. What is your telephone number and preferred e-mail address?   
6. Would you be willing to share your perceptions about about the effects of the 
current federal stem cell policy on stem cell research in the United States, the 
moral disagreement with stem cell research, and your recommendations to 
improve stem cell research policy in the United States, which will take 
approximately 45 minutes in a telephone interview? 
7. If you participate in the study, would you be willing to verify the accuracy on 
your interview transcript that would be e-mailed to you at a later date after the 
interview has been completed and the interview has been transcribed? 
8. Is there another stem cell researcher who works at a government organization, 
private company, or university; a stem cell stakeholder who is a faculty 
member at a univeristy where stem cell research is being conducted; or an 
investor who works for a government organization or private company that 
invests in stem cell research in the United States that you would like to 
recommend to be a participant in this study? If so, please provide their 
personal contact information or public work contact information that is 
available online, but please do not provide their nonpublic work contact 





Appendix B: Interview Guide 
Interview Guide 
Introduction 
• Welcome participant and introduce myself. 
• Explain the general purpose of the interview and why the participant was chosen. 
• Discuss the purpose and process of interview. 
• Explain the presence and purpose of the recording equipment. 
• Outline general ground rules and interview guidelines such as being prepared for 
the interviewer to interrupt to assure that all the topics can be covered. 
• Address the assurance of confidentiality. 
• Inform the participant that information discussed is going to be analyzed in 
aggregate form and participant’s name will not be used in any analysis of the 
interview. 
Discussion Purpose 
 The purpose of study is to explore the perceptions of stem cell researchers, 
stakeholders, and investors in the United States about the effects of the current federal 
stem cell policy on stem cell research in the United States, the moral disagreement with 
stem cell research, and their recommendations to improve stem cell research policy in the 
United States.  
Discussion Guidelines 




 Please respond directly to the questions and if you don’t understand the question, 
please let me know. I am here to ask questions, listen, and answer any questions you 
might have. If we seem to get stuck on a topic, I may interrupt you. I will keep your 
identity, participation, and remarks private. Please speak openly and honestly. This 
session will be tape recorded because I do not want to miss any comments. 
General Instructions 
When responding to questions that will be asked of you in the interview, please 
exclude all identifying information, such as your name and names of other parties. Your 
identity will be kept confidential and any information that will permit identification will 
be removed from the analysis.  
Possible Probes 
• Could you elaborate more on that? 
• That was helpful, but could you provide more detail? 
• Your example was helpful, but can you give me another example to help me 
understand further? 
Interview Questions 
1. What do you perceive to be the effects of the current federal stem cell policy on 
stem cell research in the United States? If clarity about the federal stem cell 
policy is needed: President Obama issued an executive order, titled, Removing 
Barriers to Responsible Scientific Research Involving Human Stem Cells, with the 
goal of strengthening human embryonic stem cell research in the United States 




Services, through the Director of the NIH, may support and conduct responsible, 
scientifically worthy human stem cell research, including human embryonic stem 
cell research, to the extent permitted by law (Obama, 2009). However, President 
Obama’s new stem cell policy did not approve the 21 hESC lines that were 
eligible under the Bush administration (Levine, 2011).  
2. What are your thoughts about the National Institutes of Health strict ethical 
policies regarding human embryonic stem cell research and its effect on stem cell 
research in the United States? If clarity about the NIH policy is needed: Human 
embryonic stem cell lines have to meet the National Institutes of Health strict 
ethical policies (Nature Cell Biology, 2010). Applicant institutions proposing 
research using human embryonic stem cells derived from embryos donated in the 
United States should be derived from human embryos that were created using in 
vitro fertilization for reproductive purposes and were no longer needed for this 
purpose (NIH, 2015a). In addition, the human embryonic stem cells were donated 
by individuals who sought reproductive treatment and gave voluntary written 
consent for the human embryos to be used for research purposes (NIH, 2015a). 
3. What are your perceptions about whether U.S. stem cell researchers have really 
benefited from President Obama’s more relaxed funding policies? 
4. What are your thoughts about how the Dickey-Wicker Amendment restricts the 
use of federal funds for creating, destroying, or knowingly injuring human 





5. What are your perceptions on how the U.S. stem cell policy has diminished or 
improved U.S. stem cell research competitiveness with other countries? 
6. What are your thoughts on how the U.S. can become more competitive with other 
countries that they lag behind in relation to stem cell research? 
7. What are your perceptions about the moral disagreement with stem cell research? 
8. What are your thoughts on how stem cell proponents and opponents can 
compromise on stem cell research? 
9. What do you recommend to improve stem cell research policy in the United 
States? 
Conclusion 
• Discuss the transcription review process with participant, ask and answer any 




Appendix C: NIH Certificate 
Certificate of Completion 
The National Institutes of Health (NIH) Office of Extramural Research 
certifies that Dorothy Moore successfully completed the NIH Web-
based training course “Protecting Human Research Participants”. 
Date of completion: 08/06/2015  






Appendix D: Thematic Analysis Step 1 or Categorization of Text 
Research Question 1 
Research Question 1: What are U.S. stem cell researchers’, stakeholders’, and 
investors’ perceptions about the effects of the current federal stem cell policy on 
stem cell research in the United States? 
 
Thematic Label 1: What are U.S. stem cell researchers’, stakeholders’, and 
investors’ perceptions about the effects of the current federal stem cell policy on 
stem cell research in the United States. 
 
Theme 1: Perceptions of the effects of the current federal stem cell policy. 
 
Subtheme 1: Overall perceptions: 
 
Participant 12 stated: 
I do believe the current federal policy is for the betterment of science research and will 
have positive long-term effects on disease and disease treatment. 
 
Participant 13 related: 
Current federal stem cell policy has certainly boosted stem cell research considerably 
over the last 7 years. [The Obama administration’s policy] has allowed stem cell 
researchers more flexibility in choosing cell lines of interest. In addition, there has been 
more investment in stem cell research, which has resulted in significant milestones being 
achieved in stem cell research in the United States. Importantly, multiple clinical trials 
have been initiated for stem cell therapy of degenerative diseases. 
 
Participant 21 reported: 
The current policy is fairly permissive and does not limit scientists’ abilities to address 
most interesting and important questions. 
  
Participant 7 noted: 
The policy is restrictive. Although I appreciate the thoughtfulness behind the policy, it is 
still restrictive in terms of access to the research taking place. 
 
Participant 6 stated:  
The current federal stem cell policy makes it easier to do more research, but funding is 
still slow to roll out, due to past policies and restrictions.  
 




The current policy does not give access to the research as it should. With all the testing 
that is taking place, the benefit from stem cell is still not fully realized by many because 
of access. 
 
Participant 14 reported: 
Stem cell policy has an impact. Major research companies move their stem cell research 
division to other countries where scientists are permitted to conduct research without any 
restriction.  
 
Participant 15 stated:  
These policies limit stem embryonic cell research and more importantly rapid 
advancement in therapeutic approaches and applications. The current stem cell policy 
does not affect my research. To my knowledge, as a scientist, progress has been made 
despite strict current policies. 
 
Participant 20 related:  
This policy does limit ongoing research in this important area. However, I understand 
that there is limited impact on research. 
 
Participant 16 reported: 
There may be limits on what research could be carried out using ESCs with federal funds, 
but most research is concentrated with the use of adult stems in the United States. 
 
Participant 10 stated: 
The current research that I am a part of is not affected by federal or state regulations. We 
are using iPS cells, induced pluripotent stem cells, which are generated from fibroblasts 
donated by patients. 
 
Participant 11 noted: 
I feel that governmental restrictions are less and less of a concern as research increasingly 
includes adult-derived stem cells and iPS cells. Few of my colleagues are performing 
research with ESCs, though this may change concurrently with changes in policy.  
 
Participant 18 stated: 
The policy does not have an impact, as research is more and more inclusive of adult stem 
cells versus ESCs. 
 
Participant 19 stated: 
Current policy is not an issue as ESC research is being done less and more adult stem 
research is being completed. 
 




The current policy as it stands is not very restrictive since people are able to use ESC 
lines as well as adult derived stem cells. In addition, ESCs can be derived from 
nonhumans as well as produced from skin cells. 
 
Participant 17 noted: 
Stem cell policy has a limited impact, if any, at this time.  
 
Participant 15 stated: 
[Federal policy] does not allow us to compare data generated from adult versus ESC 
research, which [is] the only way to know if the use of iPS cells is comparable. 
 
Participant 8 stated: 
If you mean the ban on federal funding for embryonic research put in place during the 
Bush administration and lifted during the Obama administration, it only banned the use of 
taxpayer dollars to pay for embryonic research. Taxpayer dollars have always been a 
significant source of funding for adult stem cell research and now iPS cell research. The 
ban only meant that if you wanted to do ESC research, you’d have to get private grants or 
venture capital to cover the costs. ESC research continued in labs across the country, but 
was largely leapfrogged by the discovery of iPS cells in 2012.  
 
Subtheme 2: Perceptions of the Obama administration’s funding policy: 
 
Participant 13 stated: 
Significant progress has been made in stem cell research over the last 7-plus years and we 
are at the cusp of realization of its clinical potential. In addition, there has been a great 
push for using stem cell as disease models and for in vitro toxicity testing. All these 
advancements can be largely contributed to President Obama’s funding policies.  
 
Participant 21 stated: 
The relaxation of funding policies during the Obama administration has almost certainly 
benefitted scientists. This has come, in part, through access to a greater array of hESC 
lines and through a greater normalization of the field, reducing some of the complications 
associated with working with these cells. 
 
Participant 4 elaborated further on the benefits of the relaxed funding policy: 
U.S. researchers have absolutely benefitted from the relaxed policies governing the use of 
NIH funds to work on already established lines of hESCs. For example, there is ample 
data to show that different lines of stem cells have intrinsic differences in their ability to 
differentiate into different lineages. Having the ability to use multiple lines of ESCs in 
NIH-funded research allows scientists to characterize these differences and explore the 
causes to ultimately help understand fundamental properties of differentiation. We are a 




Participant 12 noted that relaxed federal funding policies stimulated private funding 
sources:  
Relaxed funding policies lead to more pharma and private donations, which is a good 
thing, and stem cell researchers have been the beneficiary. 
 
Participants 4, 5, 10, 14, 16, 17, 19, and 20 gave responses that agreed in substance 
with those quoted above, describing the Obama administration’s funding policy as 
beneficial to stem cell researchers. 
 
Participant 2 believed that the current funding policy was beneficial and added: 
It’s easier for researchers to now use federal funds to work with new ESC lines. That 
wasn’t true for most of the United States before President Obama lifted the federal 
restrictions. 
 
Participant 2 also noted that the relaxation of funding restrictions was not equally 
urgent for all researchers and stated: 
President Obama’s decision to lift the restrictions imposed by President Bush has 
certainly made it a lot easier for researchers around the United States to do work 
involving ESCs. Those restrictions were not really a problem as the voters of this state 
created CIRM through Proposition 71 in 2004, giving the stem cell agency $3 billion to 
fund this kind of work California. While researchers in other states faced huge barriers 
and strict limits on what they could use their stem cell research funding for, in California, 
we had no such problems as we could bypass the Feds and fund it ourselves.  
 
Participant 3 described the lingering effects of the more stringent policies of the 
Bush administration as having a negative effect on current research in the United 
States. This participant stated: 
Not sure if anyone has benefitted from the more relaxed policy as more people are doing 
more research outside the United States, which is a push from the Bush legacy. Once you 
are banned from doing something and you move on to something else, you don’t usually 
turn back.  
 
Participant 15 stated: 
Yes, scientific research has benefitted from these policies, but they did not go far enough 
to have a real impact on medical applications. 
 
Participant 4 noted that the Obama administration’s policy, which rests on an 
executive order, can be reversed by any subsequent president, such that researchers 
cannot rely on the indefinite continuation of the current funding guidelines:  
I would characterize the environment as unstable, especially around presidential 
elections, where the new president with a different ideology can rescind the order with 





Other participants expressed the perception that while the current policy was 
favorable to research, it had not been put into effect. Participant 9 stated: 
The relaxed funding policies have not really been implemented, kind of like travel to 
Cuba, it really is still incredibly difficult. 
 
Similarly, Participant 6 stated: 
The full benefit has not been realized, but clearly there are benefits. 
 
Participant 7 suggested a reason why the policy might have failed to have its 
intended effect:  
[The policy] is definitely a good thing, but we still are stagnant in the research and its 
use. The benefit has not increased much from 2009 as the bipartisan support needed is not 
available. 
 
This response was echoed by Participant 1: 
In 2009, when President Obama did the EO that removed the barriers to responsible 
research, it should have been a good thing, but we still are stagnant in the research and its 
use; therefore, the benefit has not increased much from 2009 as the bipartisan support 
needed is not available.  
 
The alternatives to hESC were also described as depriving President Obama’s EO 
of some of its effect. Participant 5 stated: 
Researchers have definitely benefitted from the relaxed restrictions, as there are many 
more hESC lines currently eligible for research supported by NIH. That said, the advent 
of iPS cell has to some extent lessened the need for new hESC lines. Additionally, the 
preponderance of the Bush lines, those approved for research under President Bush, 
appear to remain the most heavily used cell lines because researchers are comfortable 
with them and have been using them for years.  
 
Participant 8 indicated that President Obama’s executive order had been deprived 
of much of its intended force by the nature of hESCs: 
I don’t think [the EO] makes any difference. For most researchers, the problem with 
embryonic cells is less ethical than scientific. Embryonic cells multiply at an extremely 
rapid pace and have a propensity to form cancers. They can be used for disease modeling 
and drug screening in a lab, but will not be used in people, with the exception of a very 
small number of ophthalmology projects, until their cancer-forming properties can be 
controlled. In the meantime, iPS cells have leapfrogged the need to use them.  
 
Subtheme 3: Perceptions of the NIH’s ethical policy: 
 
Most participants expressed agreement with the NIH ethical policy. Participant 13 





The NIH policy restricted the generation of new stem cell lines. However, there needs to 
be strict supervision on such ethical policies. ESCs have great power and ensuring that it 
is handled responsibly is possible only through strict supervision.  
 
Participant 4 expressed a similar perception, citing the importance of ethical science 
and the value of the NIH policy in promoting it: 
I think all research should be done ethically by following approved and vetted standards. 
Embryonic and adult stem cell research is no different. The ISSCR helped create the first 
set of standards on ethical embryonic and adult stem cell research and recently released 
an updated set of guidelines. There are many benefits of the new policies and procedures 
that NIH uses to vet the provenance of the lines, including protecting patients and donors 
and helping to maintain the integrity of the process. All scientific research benefits by 
following ethical scientific practices.  
  
Participant 1 stated: 
I would describe the current ethical policies as particularly strict. 
 
Participant 21 stated:  
The NIH ethical guidelines represent, in my view, a reasonable compromise between the 
obligation to protect embryo and gamete donors and the desire to help advance the 
science. 
 
Participants 3, 12, and 19 also described the policy as “strict” while expressing 
agreement with it.   
 
Participant 3 related: 
NIH strict policy . . . promoted the idea of nonembryonic use and moved research into a 
different path, which is more universally useful. It also brought up the ethical issue of 
how many embryos would be sacrificed to create one transplant, which then created the 
ethical issue of who could afford to use this process, in most cases, meaning only wealthy 
people could afford to have a chance at using the therapy from embryonic tissues. ESCs 
are not very scalable, so to have something of value, the product or service must be 
scalable. 
 
Participants 6, 10, 11, 14, 16, 17, 18, and 20 agreed with the policy without 
reservation.   
 
Other participants expressed misgivings about the policy. Participant 9 stated: 
[The NIH ethical policy] is scientifically informed regarding safety. It is dynamic as new 
therapies are always developing. The ethical interpretations of ESC use are not 






Participant 8 expressed the belief that the ostensibly ethical policy was actually 
unrelated to ethics:  
ESCs used for research purposes have always been harvested from IVF clinics with the 
express permission of the individuals involved. The NIH guidelines do not constitute 
ethical policy, they just clarify the source of cells.  
 
Participant 7 described the policy as a potential cause of misunderstanding:  
The NIH is legally bound to the policies, and as such, has a limiting impact and causes 
confusion in people’s minds about the differences between human embryonic and adult 
stem cells and their uses for research. 
 
Participant 5 agreed with the ethics of the policy and believed that certain 
additional issues remained unaddressed, stating: 
Informed consent for the donors of embryos used to create hESC lines remains an 
important policy. 
 
Participant 5 added two objections. The first of these objections was expressed in 
these terms:  
The NIH policy on using only embryos left over from IVF may skew the source of new 
lines to less than healthy embryos, as these are more likely not to be implanted.  
The second objection was stated as follows: 
The FDA has not kept up with the science in regard to its guidance or requirements for 
preclinical studies needed to move stem cell-based therapies into clinical trials. I am not 
arguing for following the Japanese model and I also have grave misgivings about the 
REGROW Act, rather I would like to see the FDA issue clear guidance and play a more 
active role in regulating the unregulated stem cell clinics currently marketing 
unapproved, untested therapies. Finally, U.S. policy with regard to preventing the FDA 
from even considering applications involving genetic engineering [or] modification of 
human embryos should not be enshrined perpetually in law as the Dickey-Wicker 
Amendment has become . . . . The FDA’s process is slow, laborious, and highly 
inconsistent. It means that therapies can take up to 20 years and billions of dollars to get 
approval. Very few companies can afford that time or money.  
 
Subtheme 4: Perceptions of the Dickey-Wicker Amendment: 
 
Participants’ opinions of the amendment were divided, with some interviewees 
expressing strong disagreement for various reasons, but with a number expressing 
assent (i.e., Participants 1, 10, 11, 12, 14, 16, 18, and 20). Of those participants who 
disagreed, three related that the amendment’s impetus was irrational. Participant 9 
stated: 
I strongly disagree [with the amendment]. This is a religious agenda. Females can discard 
embryos in late menstruation, yet this is not regulated. We don’t scoop them up, protect 




Participant 7 stated:  
The amendment is unfortunate. It created a path that is based more on people’s feelings 
than on science. 
 
Participant 5 had a legal objection:  
I think Dickey-Wicker is a clear case of the nonseparation of church and state. The 
amendment puts the beliefs of primarily one religion over that of others and instills those 
beliefs in federal legislation. 
 
Participant 5 also noted that recent technology had limited the amendment’s effect:  
Fortunately, with the advent of iPS cell technology and the continued addition to the NIH 
registry of new hESC lines created with other funds, the amendment is not the barrier it 
once was. 
 
Participant 21 also described the amendment’s restrictions as limited but still 
significant:  
State and private funding have helped work around this restriction, but this is clearly a 
key challenge for the field. 
 
Participant 13 expressed a similar opinion about the limited scope of the 
amendment, but emphasized the legislation’s negative effect on the research that fell 
within its purview: 
While it does not restrict the use of hESCs for research purposes, it still restricts the 
generation and establishment of new stem cell lines from embryos. While there needs to 
be strict supervision regarding use and destruction of embryos, with the current 
amendment, the field is restricted to the use of just handful of lines.  
 
Two participants pointed out that IVF embryos, which are not used in stem cell 
research, will usually be discarded. Participant 4 stated: 
In theory, the amendment was designed to protect embryos, but in fact it does not do so. 
Although the embryos cannot be used for federally funded research, they will likely be 
discarded when they are no longer needed for fertility treatments. 
 
Similarly, Participant 8 stated: 
You have three options for embryos that are yours and being cryopreserved at [an] IVF 
clinic: throw them away, donate them to research, or continue to cover the costs of 
storing them indefinitely. Most of them are discarded. 
 
Participant 3 discussed the difficulty of evaluating the amendment: 
This is a complex issue that deals with ethical issues like the use of eggs [in an] in-vitro 
sterilization clinic . . . . Should they be implanted in another female or used to further 
research study? So, with something so complex, it may be best to not complicate the 




cells of embryos can become abused if people believe there is a financial gain from it, so 
it must be clear what the benefit will be or should be. I do not have an answer for this 
question and believe it needs to be discussed more at a broader level.  
 
Participant 17 also believed that more information was needed before the 
amendment could be properly evaluated and that enforcing it was a more prudent 
course of action than overturning it:  
The Dickey-Wicker Amendment should remain as is until there is a clear understanding 
of what and how hESC can be a benefit. 
 
Participant 1 also viewed the amendment as a prudent precaution:  
I believe that the Dickey-Wicker Amendment should stay in place. As with any 
exploratory science, one can go overboard, so the amendment should stay in place and 
continue to be reviewed annually for changes to funding, if necessary. 
 
Participant 6 agreed with the amendment, but emphasized its negative effect on the 
funding of research:  
The Dickey-Wicker Amendment is needed, but it is limiting, where federal funds are 
concerned. 
 
Participant 2 pointed that the effect on funding was limited: 
While the Dickey-Wicker Amendment prohibits the use of federal funds for research on 
human embryos, it does not, at least under the current interpretation, limit the use of 
federal funds for research on embryonic cell lines. So in that sense, it really has a limited 
impact on stem cell research. Of course, that could change with a different 
administration.  
 
Theme 5: Perceptions of competition between the United States and other countries:  
 
A number of respondents did not believe that the United States lagged behind other 
countries (i.e., Participants 2, 5, 6, 10, 11, 12, 14, 16, 18, 19, and 21).  
 
Participant 10 believed that federal policy had no effect on U.S. competitiveness:  
I do not think the policy has either diminished or improved competitiveness with other 
countries. 
 
Participant 18 expressed the same perception:  
Policies have no effect on improving or diminishing competitiveness with other 
countries. 
 





Scientists and institutions worked around [the Bush administration’s funding restrictions], 
with state and private funding and the United States is clearly among the top tier of 
countries producing key stem cell research advances.  
 
Participant 5 also described U.S. researchers as succeeding despite the federal 
policy: 
The United States remains in the forefront, but other countries, the UK in particular, have 
in some ways more opportunities to conduct research that it is not possible to conduct 
here. My impression is that at least parts of the EU also allow more. Fortunately, the 
sheer size of the biomedical research enterprise and the amount of funds the United States 
contributes to research allow the United States to remain competitive in all but a few 
areas.  
 
Participant 2 echoed Participant 21’s reference to the restrictive funding policy of 
the Bush administration:  
The restrictions [during the Bush administration] clearly put U.S. researchers at a 
disadvantage compared to scientists in Europe and Asia . . . [but] I don’t think the United 
States lags behind other countries any more.  In many ways, we are as advanced if not 
more so than most countries.   
 
Participant 20 shared that the Obama administration’s relaxation of funding 
restrictions had improved U.S. competitiveness. Participant 20 stated: 
Under Bush, it was too restrictive. The current policy is [a] good balance of ethics and 
ability to do research.  
 
Participant 12 stated: 
I think U.S. competitiveness has improved, as seen with the large growth within my 
group alone. From attending world and international stem cell conferences, I do not 
believe we lag in comparison with other countries. 
 
Participant 19 agreed that the situation for U.S. researchers had been improved:  
I think the policies [of the Obama administration] have helped the U.S. become more 
competitive with other countries. 
 
Similarly, Participant 7 stated: 
Obama’s more expansive policy has improved competitiveness. We are still restricted to 
the creation of new lines due to the lack of using federal funds. More people are not 
aware that this is an ongoing issue. With wider bandwidth, U.S. research could be felt on 
a global basis.  
 
Other participants agreed that federal policy had an inhibitory effect on U.S. stem 




We have not improved [and] as a country, we could be doing far more than what we are 
doing.  
 
Participant 13 related: 
U.S. stem cell policy has certainly diminished U.S. competitiveness with other countries, 
in particular Japan and Europe. Over the last 5 years, we are experiencing some boost in 
U.S.-based studies. While such studies are at the forefront, the volume of research and 
number of stem cell researchers in the United States is still limited.  
  
Participant 15 indicated that restrictions on stem cell research in the United States 
might give an advantage to other countries:  
U.S. stem cell policies might have actually boosted stem cell research in countries like 
China, since the chances for a breakthrough and the first to discovery are greatly 
increased in places other than the United States. 
 
Participant 15 also explained why U.S. researchers could not simply evade 
legislative constraints by focusing their efforts on fields of inquiry that were subject 
to fewer restrictions: 
In the current environment, scientists and the community need to fight for more relaxed 
policies on stem cell research. For now, some hESC lines are still needed for research, 
since iPS cells may not behave exactly the same as embryonic cells. Therefore, we need 
to continue to examine all stem cell types since we do not know yet which one will be the 
best to use in therapy.  
 
Participant 6 viewed the effect of federal restrictions as primarily economic:  
There are limitations in America, but companies who want to be more competitive, do 
research outside the country, and transfer it back in, so it becomes very costly for 
everyone to reap the benefits. 
 
Participants 8 and 9 agreed that federal restrictions were causing the United States 
to lag in stem cell research, with Participant 8 adding: 
Stem cell research, all research in the United States is disadvantaged by stringent FDA 
regulatory requirements, far stricter than those of other countries.  
 
Participant 4, however, while acknowledging the disadvantageous effect of federal 
policy, viewed international research as a cooperative endeavor from which the 
United States would ultimately benefit:  
[Federal policy] has certainly slowed the creation of new lines of hESCs, since that 
research can only be done using nonfederal funds. While funding science to the highest 
levels makes economic sense for our country, stem cell research is a global enterprise, 






Research Question 2 
 
Research Question 2: What are U.S. stem cell researchers’, stakeholders’, and 
investors’ perceptions about the moral disagreement with stem cell research? 
 
Thematic Label 2: What are U.S. stem cell researchers’, stakeholders’, and 
investors’ perceptions about the moral disagreement with stem cell research. 
 
Theme 2: Perceptions of the moral disagreement about stem cell research. 
 
Subtheme 1: Understanding opposition: 
 
Participants 10, 11, 12, 16, and 18 described themselves as understanding, but not as 
agreeing with the ethical objections to hESC research. Participant 12 stated:  
I understand the perceptions and concerns of the lay public in regards to the use of human 
tissues for research. 
 
Similarly, Participant 10 related:  
I understand the concerns of the general public with regards to the use and potential 
misuse of human tissues for research purposes. 
 
Two participants acknowledged the validity of disagreement but emphasized the 
necessity for an ongoing dialogue. Participant 11 stated: 
The disagreement is understandable and it is a topic worthy of ongoing discussion. 
 
Participant 16 stated: 
I am sympathetic to it, but at the same time the beneficial aspects of this research can be 
insurmountable, so there needs to be ongoing communication.  
 
Participant 18 spoke in more general terms:  
I believe everyone has their right to their own belief. 
 
Subtheme 2: Religious or moral objections:  
 
Participant 1 perceived the source of the opposition as a reason to abstain from 
giving a judgment:  
I don’t have an opinion, as a lot of the moral disagreement is related to the Christian 
views related to how embryos are being used to accomplish scientist goals.  
 
Participant 15 believed that opposition to hESC research issued from a combination 
of political calculation and misdirected sentiment: 
I do not believe there is a moral disagreement, rather a religious perception and power 




is intimately linked to politics in the United States. We have the moral obligation to save 
lives. If the material we use was procured from spontaneous abortions or medically 
recommended abortions, we are not conducting an immoral activity.  
 
Participant 2 expressed sympathy with the beliefs of opponents of stem cell 
research, but expressed a belief similar to that of Participant 15, to the effect that 
moral concern was more properly directed toward the promotion of a life-saving 
technology: 
There are many people of strong religious faith who are opposed to the use of fetal tissue 
or ESCs in research, considering these a violation of the sanctity of life. We respect those 
views completely. However, we don’t agree that either of these approaches is ethically or 
morally wrong, a view Congress has supported since the 1950s. In fact, we feel we have 
an obligation to pursue the use of these materials in scientific work because of their 
enormous potential to save the lives of millions of people around the world who are 
currently battling deadly diseases and disorders that have no cures.  
 
Participant 5 reiterated his earlier statement to the effect that moral opposition to 
stem cell research, when it took the form of legislation, was unconstitutional: 
The moral disagreement with stem cell research is rooted primarily in Christianity and . . 
. raises the beliefs of one religion, or some branches thereof, above those of others and is 
a clear instance of lack of separation of church and state. Adult stem cells are great, but 
they have limitations that cannot, yet, possibly never be overcome that hESCs do not 
have, and to hold them up as a reason not to conduct hESC research is a specious 
argument.  
 
Participant 14 noted the connection between religious opposition to hESC research 
and religious opposition to abortion: 
Many opponents of stem cell research, like religious leaders, compared stem cell research 
to abortion. For the Catholic Church, for example, life begins at conception, making the 
stem cell research comparable to homicide because it results in the destruction of many 
embryos. Although scientists are right, but from a moral standpoint, it could be conceived 
as wrong.  
 
Participant 4 made the connection between opposition to abortion and opposition to 
hESC research: 
The misperception that this issue, hESC research, is tied to abortion will forever entangle 
it in a political quagmire. The fact remains that those embryos no longer needed for 
fertility treatments will be discarded as medical waste if not donated to science or 
adopted by another couple, which is exceptionally rare. Stopping ESC research is not 
saving embryos.  
 
Participant 3 made a similar point:  




Participant 20 indicated a context for the debate by sharing the perception that the 
moral disagreement about hESC research was between an ethical consensus among 
medical professionals and the subjective reactions of some private individuals:  
This moral issue is a personal issue. The U.S. policy is in line with most bioethics 
considerations. 
 
Subtheme 3: Stem cell source:  
 
Several participants noted that the moral disagreement surrounding stem cell 
research depended to a great extent on the source of the cells in question. 
Participant 1 stated: 
In the United States, we get caught up with the logistics, such as whether the stem cells 
are being used from human embryos or from one’s own stem cells, which is two different 
processes, but is still misunderstood to this day. 
 
Participant 4 stated: 
The disagreement is fundamentally over the destruction of embryos for the purpose of 
creating lines of hESCs and not [over] stem cell research in general.  
 
For Participant 21, identifying moral concern over the embryo as the point of 
contention was a reason for pessimism about the prospects of compromise:  
The debate over the moral status of the embryo isn’t going anywhere and will continue to 
shape public opinion toward the field. 
 
Participant 4 was optimistic about the chances for a satisfactory resolution by a 
consideration of emerging technology:  
More companies are moving to fibroblast stem cell [iPS cell] research, so the issue will 
become invalid soon, essentially making it a nonissue. 
 
Subtheme 4: Reasoning:  
 
A few participants questioned the validity of the debate, not because the reason for 
disagreement was religious or moral, but because they perceived the reasoning of 
hESC research opponents as flawed. Participant 7 stated: 
It is simple, the moral disagreement is a nonissue, because if people only understood that 
the majority of the vaccines have been derived from these tissues being discussed and if 
they looked further into what the actual usage is and reasons are behind it, most people 
would understand the importance of the research.  
 
The idea that disagreement was a result of ignorance was echoed by Participant 13: 
Moral disagreements are largely from lack of scientific knowledge and factual 





Participant 17 believed that hESC research might be promoted by an appeal to 
common sense:  
I think it’s a gray area, but rather than waste stem cells, why not put them to a good use 
that benefits all humanity? 
 
Participant 8 believed that public’s understanding of the controversy was impaired 
by equivocal terminology: 
There is no moral disagreement about stem cell research. You shed your skin regularly 
because skin stem cells are constantly renewing and replacing damaged, old skin. You 
can donate a lobe of your liver and it will grow back because liver stem cells will 
regenerate it. Every tissue in your body constantly renews itself through tissue-specific 
stem cells. To say you have a moral disagreement with stem cell research is like saying 
you object to your liver. There is controversy about the use of ESCs for research, but I 
see it as a far greater issue in the lay public than it is in the research community. Most 
scientists I know find it less an ethical problem than a scientific one. Because ESCs form 
cancers, their primary contribution will continue to be disease modeling and drug 
screening. And the ethical concerns about using embryonic cells have been completely 
leapfrogged by the discovery of iPS cells. Even the Vatican supports and funds adult and 
iPS cell research. 
 
Subtheme 5: The Possibility of Compromise: 
 
Two participants believed that compromise between proponents and opponents of 
stem cell research was unlikely. Participant 4 stated: 
I don’t see how a compromise is possible.  
 
While Participant 21 left only slightly more room for optimism:  
Compromise is not likely for those with strong views on [the] moral status of the human 
embryo. 
 
Participant 5 suggested that the benefits of hESC research might gradually 
persuade its opponents:  
Unfortunately, I do not think hESC opponents are willing to compromise, but when 
hESC-based treatments [and] therapies for diseases that afflict them or their family 
members become available, I hope they will take advantage of them and maybe 
reconsider their stance.  
 
Five participants believed that deriving the necessary research materials from 
uncontroversial sources would render the debate moot. Participant 21 stated: 
Focus on less contentious technologies [such as] IPS cells and use of existing rather than 
new hESC lines offer some hope. 
 




By working to develop [and] improve lines in which ethical issues have been thoroughly 
discussed. 
 
Participant 16 stated: 
I believe that continued use of iPS cells can be considered as a compromising option. 
 
Participant 10 stated: 
I believe iPS cells are a compromise on stem cell research. 
 
However, Participant 15 pointed out that iPS cells might fail as a means of 
circumventing moral contention:  
The use of iPS cells is a compromise with stem cell research opponents; however, we do 
not yet know the real potential of this technology and its application to therapy. 
 
Other participants recommended more effective education of the public as a means 
of promoting compromise. Participant 7 placed the burden of promoting education 
on opponents of stem cell research:  
They can find compromise by asking the more meaningful questions about stem cell 
research outcomes, such as what does the research mean to my family and to the country 
now and into the future. 
 
Participant 6 placed the burden on proponents of the research, suggesting that they 
should “provide a greater understanding.”  
 
Participant 12 referred to education and the concurrent use of uncontroversial 
materials as a means of achieving a compromise: 
I believe the best compromise is using other stem cell lines beyond embryonic and 
making the public aware of the differences. For example, hMSCs, which we use, are from 
a human, adult, healthy donor and these cells have shown to be great in curing very 
devastating conditions such as stroke or cardiac problems. 
 
Research Question 3: What do U.S. stem cell researchers, stakeholders, and 
investors recommend to improve stem cell research policy in the United States? 
 
Thematic Label 3: What do U.S. stem cell researchers, stakeholders, and investors 
recommend to improve stem cell research policy in the United States. 
 
Theme 3: Policy recommendations. 
 
Subtheme 1: Funding: 
 
All six participants who made policy recommendations related to federal funding 




It’s going to take a huge investment by the government to really push this research along. 
 
Participant 8 summarized her recommendations in the form of an equation:  
Streamlined process plus money equals competitive advantage, where streamlined 
process referred to an acceleration of the FDA approval process.  
 
Participant 2 also mentioned FDA requirements:  
It’s going to take changes in the way the FDA regulates stem cell therapies to enable the 
science to move ahead as fast as it needs to. 
 
Participants 1, 9, 20, and 21 also recommended an increase in federal funding. 
 
Subtheme 2: Involving outsiders: 
 
Two participants suggested involving laypersons in the discussion. Participant 3 
recommended: 
Bringing in people from the outside and not just the professionals. 
 
Similarly, Participant 7 stated: 
Engage lay people, who are recipients of the therapy, and not just those who are 
professionals in the field.  
 
Participant 7 also elaborated on the reasons why involving the public might be an 
effective political agenda:  
People are very similar when it comes to saving lives. People respect human life and are 
more practical in their understanding if they can relate outcomes to their own family and 
loved ones. 
 
Subtheme 3: Religion: 
 
Participant 9 proposed the removal of religious agendas from the dialogue, stating: 
The ethical interpretations [to] ESC use are not scientifically informed and restrictions 
should be reevaluated without political or religious input.  
 
Participant 9 added that legislators should: 
Vote to overturn religious agendas [and] until the policies change, the science can’t move 
forward. 
 
Subtheme 4: Education: 
 
Other participants recommended various forms of education as a means of making 




Improved science education, public announcements educating the public, [and] 
encouraging open discussion of policy, ethics, and science. 
 
Participant 14 stated: 
The general public do not know enough about the benefits of stem cell research. 
Education is needed. 
 
Participant 14 recommended: 
Reaching out to our community. 
 
Similarly, Participant 17 suggested: 
Educational outreach so that both sides of the good and bad are discussed with 
stakeholders and a common, middle ground is reached. Hard to do but attemptable. 
 
Participant 19 agreed with Participant 17 in recommending even handed education:  
People need to be educated on the advantages and disadvantages. 
 
Participant 1 suggested that educational efforts should not be focused solely on the 
general public, stating: 
Educate the population and the lawmakers. 
 
